UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the Securities

Exchange Act of 1934

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:


Preliminary Proxy Statement

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

Definitive Proxy Statement

Definitive Additional Materials

Soliciting Material Pursuant to Section 240.14a-12
LIONHEART ACQUISITION CORPORATION II

Preliminary Proxy Statement

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

Definitive Proxy Statement

Definitive Additional Materials

Soliciting Material Pursuant to §240.14a-12

MSP Recovery, Inc.

(Name of Registrant as Specified Inin Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box)all boxes that apply):


No fee required.

Fee computed on table below per Exchange Act Rules 14a-6(i) (1) and 0-11.
(1)
Title

No fee required

Fee paid previously with preliminary materials

Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11


img191178444_0.jpg 

Logo 2023 Proxy Statement Notice of each class of securities to which transaction applies:

(2)
Aggregate number of securities to which transaction applies:
(3)
Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
(4)
Proposed maximum aggregate value of transaction:
(5)
Total fee paid:

Fee paid previously with preliminary materials.

Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
(1)
Amount Previously Paid:
(2)
Form, Schedule or Registration Statement No.
(3)
Filing Party:
(4)
Date Filed:
Annual Stockholders Meeting



LIONHEART ACQUISITION CORPORATION II
4218 NE 2nd Avenue
Miami,

img191178444_1.jpg 

2701 South Le Jeune Road, Floor 10

Coral Gables, Florida 33137

NOTICE OF SPECIAL MEETING OF STOCKHOLDERS
TO BE HELD JANUARY 27, 2022
TO THE STOCKHOLDERS OF LIONHEART ACQUISITION CORPORATION II:
33134

September 22, 2023

Dear fellow LifeWallet stockholders:

You are cordially invited to attend the special meeting2023 Annual Meeting of Stockholders (the “special meeting”“Annual Meeting”) of stockholders of Lionheart Acquisition Corporation IIMSP Recovery, Inc. d/b/a LifeWallet (the “Company,” “LCAP,” “we,” “us”“Company” or “our”“LifeWallet”) to be held at 11:10:00 a.m. ESTEastern Time on January 27, 2022.

Wednesday, November 1, 2023 by means of a live virtual-only on-line webcast.

The special meeting willaccompanying Notice of Annual Meeting and Proxy Statement describe the specific matters to be a completely virtual meeting of stockholders, which will be conducted via live webcast. You will be able to attend the special meeting online, vote and submit your questionsvoted upon during the specialAnnual Meeting. At the meeting, by visiting https://www.cstproxy.com/lionheartacquisitioncorpii/2022. We are pleasedwe also will report on our business and provide an opportunity for you to utilize the virtual stockholder meeting technologyask questions pertaining to (i) provide ready accessour business.

Whether you own a few or many shares of LifeWallet, and cost savings for our stockholders and the company, and (ii) to promote social distancing pursuant to guidance provided by the Center for Disease Control and the U.S. Securities and Exchange Commission due to the novel coronavirus. The virtual meeting format allows attendance from any location in the world.

Even if you are planning on attending the special meeting online, please promptly submit your proxy vote by telephone,whether or if you received a printed form of proxy in the mail, by completing, dating, signing and returning the enclosed proxy, so your shares will be represented at the special meeting. Instructions on voting your shares are on the proxy materials you received for the special meeting. Even ifnot you plan to attend the special meeting online,Annual Meeting, it is strongly recommended you complete and return your proxy card before the special meeting date, to ensureimportant that your shares will be represented at the special meeting ifAnnual Meeting. Your vote is important, and we ask that you are unable to attend.
please cast your vote as soon as possible.

The sole purposeBoard of Directors recommends that you vote: FOR the re-election of all the Class I director nominees, and FOR the ratification of the special meetingappointment of Deloitte as the independent registered public accounting firm of the Company for the 2023 fiscal year. Please refer to the accompanying Proxy Statement for detailed information on each of the proposals and the Annual Meeting.

On behalf of the Board of Directors and the officers and employees of LifeWallet, I would like to take this opportunity to thank our stockholders for their continued support of LifeWallet.

img191178444_2.jpg 

Sincerely,

img191178444_3.jpg 

John H. Ruiz

Chief Executive Officer

Chairman of the Board

LifeWallet


TABLE OF CONTENTS

Page

Notice of Annual Meeting of Stockholders

2

About the Meeting

8

Matters to Come Before the Annual Meeting

15

Proposal 1: Election of Directors

15

Proposal 2: Ratification of Independent Registered Public Accounting Firm

26

Corporate Governance

30

Audit Committee Report

40

Executive Compensation

42

Delivery of Documents to Stockholders Sharing an Address

50

Other Matters

50

Appendix A

A-1



NOTICE OF ANNUAL MEETING OF STOCKHOLDERS

for MSP Recovery, Inc. d/b/a LifeWallet

September 22, 2023

To the LifeWallet stockholders:

Notice is to consider and vote uponhereby given that the 2023 Annual Meeting of Stockholders of MSP Recovery, Inc. d/b/a LifeWallet (the “Company”) will be held at 10:00 a.m. Eastern Time on Wednesday, November 1, 2023 by means of a live, virtual-only on-line webcast for the following proposals:

purposes, as more fully described in the accompanying Proxy Statement:

1.
a proposal to amend (the “Extension Amendment”)To re-elect the Company’s Amended and Restated Certificatetwo Class I directors of Incorporation (the “charter”) to extend the date by which the Company has to consummate an initial business combination (the “Extension”) from February 18, 2022 to August 18, 2022 (the “Extended Date”) (such proposal,as Class I directors, each for a term of three years or until their successors are duly elected and qualified or until their earlier resignation or removal;
2.
To ratify the “Extension Proposal”); and

a proposal to approveappointment of Deloitte as the adjournmentindependent registered public accounting firm of the SpecialCompany for the 2023 fiscal year; and
3.
To transact any other business that is properly presented during the Annual Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies in the event that there are insufficient votes for,any adjournments or otherwise in connection with, the approvalpostponements of the Extension Amendment Proposal (such proposal, the “Adjournment Proposal”). The Adjournment Proposal will only be presented at the Special Meeting if there are not sufficient votes to approve the Extension Amendment Proposal.Annual Meeting.
The Extension Amendment and the Adjournment Proposal

These proposals are more fully described in the accompanying proxy statement.

As previously disclosed, on July 11, 2021,Proxy Statement following this Notice.

The Board of Directors recommends that you vote: (i) FOR the Company entered into a Membership Interest Purchase Agreement (as it may be amended, supplemented or otherwise modified from timere-election of Roger Meltzer and Beatriz M. Assapimonwait to time in accordance with its terms, the “MIPA”) by and among the Company, Lionheart II Holdings, LLC, a newly formed wholly owned subsidiaryserve as directors of the Company, (“Opco”), the MSP Purchased Companies (as defined in the MIPA) (collectively, “MSP”), the members of MSP (the “Members”), and John H. Ruiz, in his capacity as the representative(ii) FOR ratification of the Members (the “Members’ Representative”). Pursuant toappointment of Deloitte as our independent registered public accounting firm for the MIPA, the Members will sell and assign all of their membership interests in MSP to Opco in exchange for non-economic voting shares of Class V common stock, par value $0.0001, of the Company (“Class V Common Stock”) and non-voting economic Class B Units of Opco (“Class B Units,” and each pair consisting of one share of Class V Common Stock and one Class B Unit, an “Up-C Unit”) or, pursuant to notice delivered to the Company, with respect to all or a portion of the Up-C Units to be received by each such Member, one share of Class A Common Stock in lieu of each Up-C Unit (such transaction, the “Business Combination”).


1fiscal year ending December 31, 2023.


The purpose of the Extension Amendment Proposal and, if necessary, the Adjournment Proposal, is to allow the Company more time to complete an initial business combination. The Company’s prospectus for its initial public offering (“IPO”) and its charter provide that the Company has only until February 18, 2022 to complete an initial business combination. There may not be sufficient time to consummate the proposed Business Combination by February 18, 2022. Accordingly, the Company’s board of directors has determined that it is in the best interests of the Company’s stockholders to extend the date by which the Company has to consummate an initial business combination to the Extended Date. Notwithstanding stockholder approval of the Extension Amendment Proposal, the Company intends to consummate the Business Combination as soon as practicable.
The Company has agreed that if the Extension Amendment Proposal is approved and the Extension is implemented, it will deposit (each deposit being referred to herein as a “Deposit”) into the trust account established in connection

Along with the IPO (the “trust account”) $0.0333 for each public share that is not converted in connection with the stockholder vote to approve the Extension, for each monthly period, or portion thereof, that is needed by the Company to complete an initial business combination from and after February 18, 2022 and through and including the earlier to occurattached Proxy Statement, we are sending you copies of (i) consummation of the Company’s initial business combination and (ii) the Extended Date. Alternatively, if the Company does not have the funds necessary to make the Deposit referred to above, Lionheart Equities, LLC, our sponsor (the “Sponsor”), has agreed that it and/or any of its affiliates or designees will contribute to the Company as a loan (each loan being referred to herein as a “Contribution”) $0.0333 for each public share that is not converted in connection with the stockholder vote to approve the Extension, for each monthly period, or portion thereof, that is needed by the Company to complete an initial business combination from and after February 18, 2022 and through and including the earlier to occur of (i) consummation of the Company’s initial business combination and (ii) the Extended Date. Accordingly, if the Company takes until the Extended Date to complete an initial business combination, which would represent six (6) monthly periods through the Extended Date, the Company or the Sponsor would make Deposits or Contributions of $765,900 per month, or an aggregate of $4,595,400 (assuming no public shares were converted). Each Deposit or Contribution will be placed in the trust account within two business days prior to the beginning of the applicable monthly period (or portion thereof), other than the first Deposit or Contribution which will be madeAnnual Report on the day of the approval and implementation of the Extension Amendment Proposal. Accordingly, if the Extension Amendment Proposal is approved and the Extension is implemented and the Company takes the full time through the Extended Date to complete an initial business combination, the conversion amount per share at the special meeting for such business combination or the Company’s subsequent liquidation will be approximately $10.20 per share (without taking into account any interest), in comparison to the current conversion amount of approximately $10.00 per share. The Company and Sponsor will not make any Deposit or Contribution unless the Extension Amendment Proposal is approved and the Extension is granted. The Contribution(s) will not bear any interest and will be repayable by the Company to the Sponsor or its affiliates upon consummation of an initial business combination. The loans will be forgiven if the Company is unable to consummate an initial business combination except to the extent of any funds held outside of the trust account. The Company or the Sponsor, as applicable, will have the sole discretion whether to continue extending for additional monthly periods until the Extended Date and if the Company or the Sponsor, as applicable, determine not to continue extending for additional monthly periods, the obligation to make additional Deposits or Contributions will terminate. If this occurs, or if the Company’s board of directors otherwise determines that the Company will not be able to consummate an initial business combination by the Extended Date and does not wish to seek an additional extension, the Company would wind up the Company’s affairs and redeem 100% of the outstanding public shares in accordance with the same procedures set forth below that would be applicable if the Extension Amendment Proposal is not approved.

The holders of shares of common stock issued in the Company’s IPO (the “public shares”) may elect to convert their public shares into their pro rata portion of the funds held in the trust account (calculated as of two business days prior to the special meeting) if the Extension is implemented (the “Conversion”). Holders of public shares do not need to vote on the Extension Amendment Proposal or be a holder of record on the record date to exercise conversion rights. The per-share pro rata portion of the trust account on the record date (which is expected to be the same approximate amount two business days prior to the special meeting) was approximately $10.00. The closing price of the Company’s common stock on the record date was $9.96. Accordingly, if the market price were to remain the same until the date of the special meeting,

2


exercising conversion rights would result in a public stockholder receiving approximately $0.04 more than if he sold his stock in the open market. The Company cannot assure stockholders that they will be able to sell their shares of Company common stock in the open market, even if the market price per share is higher than the conversion price stated above, as there may not be sufficient liquidity in its securities when such stockholders wish to sell their shares.
If the Extension Amendment Proposal is not approved and we do not consummate an initial business combination by February 18, 2022 in accordance with our charter, we will (i) cease all operations exceptForm 10-K for the purposefiscal year ended December 31, 2022.

The Board of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter subject to lawfully available funds therefor, redeem 100% of the outstanding public shares with the aggregate amount then on deposit in the trust account and (iii) thereafter seek to dissolve and liquidate as described in more detail in this proxy statement.

The Adjournment Proposal, if adopted, will allow the Company’s board of directors to adjourn the special meeting to a later date or dates to permit further solicitation of proxies. The Adjournment Proposal will only be presented to our stockholders in the event that there are insufficient votes for, or otherwise in connection with, the approval of the Extension Amendment Proposal.
The Company’s board of directorsDirectors has fixed the close of business on December 31, 2021September 5, 2023 as the record date for determining the Company’sdetermination of the stockholders entitled to notice of, and to vote at, the Annual Meeting. Accordingly, only stockholders of record at the close of business on that date will be entitled to vote at the Annual Meeting. A list of the stockholders of record as of the close of business on September 5, 2023 will be available for inspection by any of our stockholders for any purpose germane to the Annual Meeting during normal business hours at our principal executive offices, 2701 South Le Jeune Road, Floor 10, Coral Gables, Florida 33134 for a period of ten days prior to the Annual Meeting.


We cordially invite you to attend the Annual Meeting. Even if you do not plan to attend the Annual Meeting, we ask that you please cast your vote as soon as possible. As more fully described in the accompanying Proxy Statement, you may revoke your proxy and reclaim your right to vote at any time prior to its use.

img191178444_4.jpg 

By order of the Board of Directors,

img191178444_5.jpg 

John H. Ruiz

Chief Executive Officer

Chairman of the Board

LifeWallet

YOUR VOTE IS IMPORTANT

Please vote via the Internet or telephone.

Internet: www.proxyvote.com/LIFW

Phone: 1-866-460-4822

If you request a proxy card, please mark, sign, and date the proxy card when received and
return it promptly in the self-addressed, stamped envelope we will provide.


PROXY STATEMENT

ANNUAL MEETING OF STOCKHOLDERS

NOVEMBER 1, 2023

This Proxy Statement contains information relating to the solicitation of proxies by the Board of Directors (the “Board”) of MSP Recovery, Inc. d/b/a LifeWallet (the “Company” or “LifeWallet”) for use at our 2023 Annual Meeting of Stockholders (“Annual Meeting”). Our Annual Meeting will be held at 10:00 a.m. Eastern Time on Wednesday, November 1, 2023 by means of a live virtual-only on-line webcast.

Only stockholders of record as of the close of business on September 5, 2023 (the “Record Date”) are entitled to receive notice of and vote during the Annual Meeting or any adjournments or postponements of the Annual Meeting. As of the Record Date, there were 332,445,943 shares of Class A common stock outstanding and 3,106,616,119 shares of Class V common stock (the “Common Stock”), issued and outstanding and entitled to vote during the Annual Meeting. In accordance with the rules of the Securities and Exchange Commission (“SEC”), we are furnishing our proxy materials, including this proxy statement and our Form 10-K for the year ended December 31, 2022, to our stockholders via the Internet. On or about September 22, 2023, we will mail to our stockholders a Notice of Internet Availability of Proxy Materials (the “Notice of Internet Availability”) that contains instructions on how to access our proxy materials on the Internet and how to vote. Stockholders may request to receive all future proxy materials in printed form by mail or electronically by email by following the instructions contained in the Notice of Internet Availability.

All references in this Proxy Statement to “we,” “us,” and “our” refer to MSP Recovery, Inc.


ABOUT LIFEWALLET

We are a leading data analytics company specializing in healthcare Claims recovery. Our Assignors are healthcare providers and payers (the “Assignors”) that have irrevocably assigned to us their recovery rights associated with certain healthcare Claims. We obtain Claims data from the Assignors and leverage our data analytics capabilities using our Claims recovery platform to identify payments that were improperly paid by our Assignors. We then seek the full recoverable amount from those parties who, under applicable law or contract, were responsible for payment (or reimbursement). Our Assignors fall into three general categories:

Medicare Advantage.Medicare Advantage organizations (“MAOs”) contract with CMS to administer Medicare benefits to Medicare beneficiaries pursuant to Medicare Advantage plans; and MAOs, in turn, contract with Medicare first-tier, downstream, and related entities to assist the MAOs in administering those Medicare benefits.

Medicaid. Health coverage provided to eligible low-income adults, children, pregnant women, elderly adults, and people with disabilities.

Commercial Insurance.Employer-sponsored or individual purchased health insurance coverage.

Our assets are generally comprised of recovery rights assigned by our Assignors relating to the improper payment of medical expenses. As opposed to service-based contracts, the entirety of these recovery rights have been irrevocably assigned to us, and because we own these rights, our recovery rights for Claims being pursued cannot be revoked.

Although our Assignors are primarily MAOs, Management Services Organizations (“MSO”) and Independent Practitioner Associations (“IPA”), we also can (and in certain cases do) provide our Claims recovery services to other entities such as:

• Health Maintenance Organizations

• Accountable Care Organizations

• Physicians

• Home Healthcare Facilities

• Self-Funded Plans

• States and Municipalities

• Skilled Nursing Facilities

• Hospitals/Health Systems

Our data recovery system operates across a Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) compliant IT platform incorporating the latest in business intelligence and data technology. Due to the sensitive nature of the data we receive from our Assignors, we ensure that our data systems comply with the security and privacy mandates under federal law. In April 2022, Marcum LLP (“Marcum”), a HITRUST authorized External Assessor Organization, completed an independent assessment of MSP Recovery’s system and service commitments, concluding that our system met the requirements to satisfy the applicable trust services criteria and HITRUST CSF criteria. This independent assessment verifies that we met the healthcare industry’s highest standards in protecting healthcare information and mitigating this risk, including compliance with HIPAA rules and regulations. On March 2, 2023, Marcum provided MSP Recovery a report demonstrating that our data recovery system’s commitments and system requirements meet or exceed the stringent SOC 2 Type II applicable trust services criteria. For our cloud computing services, we currently use the HITRUST certified Amazon Web Services (“AWS”).


The Company’s History

In April 2014, MSP Recovery’s predecessor, La Ley Recovery Systems, entered into its first assignment agreement. Later that year, MSP Recovery, LLC was founded to provide data driven solutions, and La Ley Recovery Systems filed its first lawsuit against a primary payer—Allstate Insurance Company. In late 2014, we entered into assignment agreements with our second and third Assignors. To date, we have over 160 Assignors. We have been assigned recovery rights associated with claims from all 50 states, as well as Puerto Rico.

Since 2014, we have had significant legal victories, including several significant federal appellate court wins. In these opinions, the courts agreed with us on a variety of key issues, holding that downstream entities, such as MSOs and IPAs have standing to sue primary plans under the Medicare Secondary Payer Act (“MSP Act”) and associated federal regulations (collectively, the “MSP Laws”); and that a settlement agreement with a Medicare beneficiary is evidence of constructive knowledge that the primary payer had reimbursement obligations.

Our Claims Recovery Model: Discover. Recover.

Discover.We believe our access to large volumes of data, sophisticated data analytics, and a leading technology platform provide a unique ability to discover potentially recoverable claims. Using Algorithms, we identify fraud, waste, and abuse in the Medicare, Medicaid, and commercial insurance segments. Our Algorithms have identified what we estimate to be significant value in potentially recoverable claims. Of the amount spent yearly by Medicare on medical expenses for its beneficiaries, we estimate that at least 10% are improper payments by private Medicare Advantage plans where a primary payer was responsible to make the payment. We seek recoveries of the billed amount from responsible primary payers, and in some instances, double damages and statutory interest pursuant to the MSP Laws.

img191178444_6.jpg 

Recover. We receive our recovery rights through irrevocable assignments. We pursue recoveries using a variety of methods, including, but not limited to, demand letters, litigation, private lien resolution programs, and the submission of Claims to mass tort or antitrust settlement coordinators. We quantify and pursue recoveries based on the billed amount (or full commercial value) of service rendered, as opposed to discounted paid amounts based on Medicaid or Medicare rates. Under existing statute and case law, the private cause of action under the MSP Act permits the pursuit of an award of double damages when a primary plan fails to provide for primary payment or appropriate reimbursement. In addition, the Company is entitled to pursue interest pursuant to Section 1862(b)(2)(B)(ii) of the Social Security Act and 42 C.F.R. § 411.24(m), which provides express authority to assess interest on Medicare Secondary Payer debts. As a result, we believe we are positioned to generate substantial annual recovery revenue at high profit margins for our assigned Claims. The below graphic demonstrates the difference between the Paid Amount, the Billed Amount, and the potential for double damages.

img191178444_7.jpg 

The LifeWallet Ecosystem

In January 2022, the Company announced the launch of LifeWallet—a versatile, scalable, and expandable ecosystem, where tokenized data is stored in a secure, user friendly platform with multiple


applications. LifeWallet is expected to provide real-time analytics at the special meetingpoint of care, employing sophisticated data analytics to enable informed decision-making and any adjournment thereof. Only holdersimproved patient outcomes. LifeWallet is being engineered to help to identify primary insurers, assisting providers in receiving reasonable and customary rates for accident-related treatment, shortening the company’s collection time frame, and increasing revenue visibility and predictability. The platform aims to avoid the improper documenting of recordmedical claims that can lead to improper billing, thereby preventing fraud, waste, and abuse, and is also expected to provide an application programming interface that allows patients to gain immediate access to all of their medical records when seeking medical treatment. LifeWallet is in continuous development to provide innovative data solutions for a variety of industries, including, but not limited to, sports, education, legal, and healthcare, incorporating extensive privacy and security standards including HIPAA compliance.

For more information about LifeWallet, please refer to our website at www.LifeWallet.com.


ABOUT THE MEETING

What is the date, time, and place of the Company’s common stockAnnual Meeting?

LifeWallet’s 2023 Annual Stockholders’ Meeting will be held on Wednesday, November 1, 2023, beginning at 10:00 a.m. Eastern Time, by means of a live virtual-only on-line webcast.

What is the purpose of the Annual Meeting?

At the Annual Meeting, our stockholders will act upon the matters outlined in the notice of meeting on the cover page of this proxy statement, consisting of:

1.
To re-elect two Class I directors of the Company as Class I directors, each for a term of three years or until their successors are duly elected and qualified or until their earlier resignation or removal;
2.
To ratify the appointment of Deloitte as the independent registered public accounting firm of the Company for the 2023 fiscal year; and
3.
To transact any other business that date are entitled to have their votes counted atis properly presented during the special meetingAnnual Meeting or any adjournment thereof. A complete listadjournments or postponements of stockholders of recordthe Annual Meeting.

Who is entitled to vote at the specialmeeting?

Only our stockholders of record at the close of business on September 5, 2023, the record date for the meeting, are entitled to receive notice of and to participate in the Annual Meeting. If you were a stockholder of record on that date, you will be entitled to vote all of the shares you held on that date at the meeting, or any postponement(s) or adjournment(s) of the meeting. As of the record date, there were 332,445,943 shares of Class A common stock outstanding and 3,106,616,119 shares of Class V common stock outstanding , all of which are entitled to be voted at the Annual Meeting.

A list of stockholders will be available at our headquarters at 2701 South Le Jeune Road, Floor 10, Coral Gables, Florida 33134 for a period of ten days before the special meeting at the Company’s principal executive offices for inspection by stockholders during ordinary business hours for any purpose germaneprior to the special meeting.

After careful consideration of all relevant factors,Annual Meeting.

What are the Company’s board of directors has determined that (i) the Extension Amendment Proposal is fair to and in the best interestsvoting rights of the Company and itsholders of our Common Stock?

Holders of our Common Stock are entitled to one vote per share on each matter that is submitted to stockholders has declared it advisable and recommends that you vote or give instruction to vote “FOR” such proposal; and (ii) recommends that you vote or give instruction to vote “FOR”for approval.

How can I attend the Adjournment Proposal.

Enclosed is the proxy statement containing detailed information concerning the Extension Amendment Proposal, the Adjournment Proposal and the special meeting. Whether or not you planAnnual Meeting?

In order to attend the specialAnnual Meeting, you must register in advance at https://www.proxydocs.com/LIFW. Upon completing your registration, you will receive further instructions via email, including your unique link that will allow you access to the meeting we urgeand will also permit you to read this material carefullyvote and vote your shares.

I look forwardsubmit questions during the Annual Meeting. Please be sure to seeing you at the special meeting.
January 4, 2022
By Order of the Board of Directors
/s/ Ophir Sternberg
Chairman of the Board
Your vote is important. Please sign, date and returnfollow instructions found on your proxy card as soon as possibleand/or voting authorization form and subsequent instructions that will be delivered to make sure that your shares are represented atyou via email. You will find more information on the special meeting. matters for voting on the following pages.


If you are a stockholder of record, you may also cast your vote by using the Internet, by telephone, by mail, or during the Annual Meeting via the Internet. If you are a beneficial owner, please follow the voting instructions provided in person at the special meeting. If your shares are held in an account at a brokerage firm or bank,notice you must instructreceive from your broker, bank, or bank howother nominee, and direct such organization to vote your shares or you may cast your vote in person at the special meeting by obtaining a proxy from your brokerage firm or bank. Your failure to vote or instruct your broker or bank how to vote will have the same effect as voting against each of the proposals.

Important Notice Regarding the Availability of Proxy Materials for the Special Meeting of Stockholders to be held on January 27, 2022: This notice of meeting and the accompanying proxy statement are available at https://www.cstproxy.com/lionheartacquisitioncorpii/2022.

3


LIONHEART ACQUISITION CORPORATION II
4218 NE 2nd Avenue
Miami, Florida 33138
NOTICE OF SPECIAL MEETING OF STOCKHOLDERS
TO BE HELD JANUARY 27, 2022
PROXY STATEMENT
Lionheart Acquisition Corporation II (the “Company,” “LCAP,” “we,” “us” or “our”), a Delaware corporation, is providing this proxy statement in connection with the solicitation by the Board of proxies to be voted at the special meeting to be held on January 27, 2022 as a virtual meeting. You will be able to attend, vote your shares, and submit questions during the special meeting via a live webcast available at https://www.cstproxy.com/lionheartacquisitioncorpii/2022.
At the special meeting, the following proposals will be considered and voted upon:

a proposal to amend the Company’s Amended and Restated Certificate of Incorporation (the “charter”) to extend the date by which the Company has to consummate an initial business combination (the “Extension”) from February 18, 2022 to August 18, 2022 (the “Extended Date”) (such proposal, the “Extension Amendment Proposal”); and

a proposal to approve the adjournment of the Special Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of the Extension Amendment Proposal (such proposal, the “Adjournment Proposal”). The Adjournment Proposal will only be presented at the Special Meeting if there are not sufficient votes to approve the Extension Amendment Proposal.
As previously disclosed, on July 11, 2021, the Company entered into a Membership Interest Purchase Agreement (as it may be amended, supplemented or otherwise modified from time to time in accordance with its terms,your instructions. A beneficial holder may also attend the “MIPA”) by and amongAnnual Meeting, but because a beneficial owner is not a stockholder of record, you may not vote during the Company, Lionheart II Holdings, LLC,Annual Meeting unless you obtain a newly formed wholly owned subsidiary“legal proxy” from the organization that holds your shares, giving you the right to vote the shares during the Annual Meeting.

As part of the Company (“Opco”),registration process, you must enter the MSP Purchased Companies (as definedcontrol number located on your proxy card, voting instruction form, or Notice of Internet Availability. If you are a beneficial owner of shares registered in the MIPA) (collectively, “MSP”),name of a broker, bank, or other nominee, you will also need to provide the membersregistered name on your account and the name of MSP (the “Members”), and John H. Ruiz, in his capacityyour broker, bank, or other nominee as the representativepart of the Members (the “Members’ Representative”). Pursuantregistration process.

On the day of the Annual Meeting, stockholders may begin to log in to the MIPA,virtual-only Annual Meeting 15 minutes prior to the MembersAnnual Meeting. The Annual Meeting will sellbegin promptly at 10:00 a.m. Eastern Time.

What constitutes a quorum?

The presence at the meeting, in person, or by proxy, of the holders of Common Stock representing a majority of the combined voting power of our Common Stock on the record date will constitute a quorum, permitting the meeting to conduct its business. As of the record date, there were 332,445,943 shares of Class A common stock outstanding and assign all of their membership interests in MSP to Opco in exchange for non-economic voting3,106,616,119 shares of Class V common stock par value $0.0001,outstanding, all of the Company (“Class V Common Stock”) and non-voting economic Class B Units of Opco (“Class B Units,” and each pair consisting of one share of Class V Common Stock and one Class B Unit, an “Up-C Unit”) or, pursuant to notice delivered to the Company, with respect to all or a portion of the Up-C Units to be received by each such Member, one share of Class A Common Stock in lieu of each Up-C Unit (such transaction, the “Business Combination”).

The Company’s prospectus for its initial public offering (“IPO”) and its charter provide that the Company has only until February 18, 2022 to complete an initial business combination. There may not be sufficient time to consummate the proposed Business Combination with MSP by February 18, 2022. Accordingly, the Company’s board of directors has determined that it is in the best interests of the Company’s stockholders to extend the date by which the Company has to consummate an initial business combination to the Extended Date. Notwithstanding stockholder approval of the Extension Amendment Proposal, the Company intends to consummate the Business Combination as soon as practicable.
The holders of shares of common stock issued in the IPO (the “public shares”) may elect to convert their public shares into their pro rata portion of the funds held in the trust account established at the time of the IPO (the “trust account”) if the Extension is implemented (the “Conversion”). Holders of public shares do not need to vote on the Extension Amendment Proposal or be a holder of record on the record date to exercise conversion rights.
Approval of the Extension Amendment Proposal is a condition to the implementation of the Extension. In addition, we will not proceed with the Extension if we do not have at least $5,000,001 of net tangible assets following approval of the Extension Amendment Proposal, after taking into account the Conversion.

4


If the Extension Amendment Proposal is approved, the amount remaining in the trust account may be only a small fraction of the approximately $230.0 million that was in the trust account as of the record date. In such event, the Company may need to obtain additional funds to complete a proposed business combination and there can be no assurance that such funds will be available on terms acceptable to the parties or at all. Additionally, if the Extension Amendment Proposal is approved, the Company’s warrants will remain outstanding in accordance with their existing terms.
The Company has agreed that if the Extension Amendment Proposal is approved and the Extension is implemented, it will deposit (each deposit being referred to herein as a “Deposit”) into the trust account established in connection with the IPO (the “trust account”) $0.0333 for each public share that is not converted in connection with the stockholder vote to approve the Extension, for each monthly period, or portion thereof, that is needed by the Company to complete an initial business combination from and after February 18, 2022 and through and including the earlier to occur of (i) consummation of the Company’s initial business combination and (ii) the Extended Date. Alternatively, if the Company does not have the funds necessary to make the Deposit referred to above, Lionheart Equities, LLC, our sponsor (the “Sponsor”), has agreed that it and/or any of its affiliates or designees will contribute to the Company as a loan (each loan being referred to herein as a “Contribution”) $0.0333 for each public share that is not converted in connection with the stockholder vote to approve the Extension, for each monthly period, or portion thereof, that is needed by the Company to complete an initial business combination from and after February 18, 2022 and through and including the earlier to occur of (i) consummation of the Company’s initial business combination and (ii) the Extended Date. Accordingly, if the Company takes until the Extended Date to complete an initial business combination, which would represent six (6) monthly periods through the Extended Date, the Company or the Sponsor would make Deposits or Contributions of $765,900 per month, or an aggregate of $4,595,400 (assuming no public shares were converted). Each Deposit or Contribution will be placed in the trust account within two business days prior to the beginning of the applicable monthly period (or portion thereof), other than the first Deposit or Contribution which will be made on the day of the approval and implementation of the Extension Amendment Proposal. Accordingly, if the Extension Amendment Proposal is approved and the Extension is implemented and the Company takes the full time through the Extended Date to complete an initial business combination, the conversion amount per share at the special meeting for such business combination or the Company’s subsequent liquidation will be approximately $10.20 per share (without taking into account any interest), in comparison to the current conversion amount of approximately $10.00 per share. The Company and Sponsor will not make any Deposit or Contribution unless the Extension Amendment Proposal is approved and the Extension is granted. The Contribution(s) will not bear any interest and will be repayable by the Company to the Sponsor or its affiliates upon consummation of an initial business combination. The loans will be forgiven if the Company is unable to consummate an initial business combination except to the extent of any funds held outside of the trust account. The Company or the Sponsor, as applicable, will have the sole discretion whether to continue extending for additional monthly periods until the Extended Date and if the Company or the Sponsor, as applicable, determine not to continue extending for additional monthly periods, the obligation to make additional Deposits or Contributions will terminate. If this occurs, or if the Company’s board of directors otherwise determines that the Company will not be able to consummate an initial business combination by the Extended Date and does not wish to seek an additional extension, the Company would wind up the Company’s affairs and redeem 100% of the outstanding public shares in accordance with the same procedures set forth below that would be applicable if the Extension Amendment Proposal is not approved.
If the Extension Amendment Proposal is not approved and we do not consummate an initial business combination by February 18, 2022 in accordance with our charter, we will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter subject to lawfully available funds therefor, redeem 100% of the outstanding public shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including any interest but net of taxes payable, divided by the number of then outstanding public shares, which redemption will completely extinguish public stockholders’ rights as stockholders (including the right to receive further liquidation distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of our remaining stockholders and our board of directors, dissolve and liquidate, subject (in the case of (ii) and (iii) above) to our obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law.

5


The Adjournment Proposal, if adopted, will allow the Company’s board of directors to adjourn the special meeting to a later date or dates to permit further solicitation of proxies. The Adjournment Proposal will only be presented to our stockholders in the event that there are insufficient votes for, or otherwise in connection with, the approval of the Extension Amendment Proposal.
The holders of shares of common stock issued prior to the IPO (“founder shares”) have waived their rights to participate in any liquidation distribution with respect to the 5,750,000 founder shares as well as the shares (“private shares”) included in the 650,000 units (“private placement units”) purchased by them simultaneously with the IPO. As a consequence of such waivers, a liquidating distribution will be made only with respect to the public shares. There will be no distribution from the trust account with respect to the Company’s warrants, which will expire worthless in the event we wind up.
If the Extension Amendment Proposal is not approved, the Company does not consummate an initial business combination by February 18, 2022, and the Company liquidates, the Sponsor has agreed that it will be liable to us if and to the extent any claims by a third party for services rendered or products sold to us, or a prospective target business with which we have entered into a written letter of intent, confidentiality or similar agreement or business combination agreement, reduce the amount of funds in the trust account to below the lesser of (i) $10.00 per public share and (ii) the actual amount per public share held in the trust account as of the date of the liquidation of the trust account, if less than $10.00 per share due to reductions in the value of the trust assets, less taxes payable, provided that such liability will not apply to any claims by a third party or prospective target business who executed a waiver of any and all rights to the monies held in the trust account (whether or not such waiver is enforceable) nor will it apply to any claims under our indemnity of the underwriters of our IPO against certain liabilities, including liabilities under the Securities Act. In the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible for such third party claims. Furthermore, it will not be liable to our public stockholders and instead will only have liability to us. There is no assurance, however, that it will be able to satisfy those obligations to us. Based on the cash available to the Company outside of its trust account for working capital and the Company’s outstanding expenses owed to all creditors (both those that have signed trust fund waivers and those that have not), it is not anticipated that the Sponsor will have any indemnification obligations. Accordingly, regardless of whether an indemnification obligation exists, the per share liquidation price for the public shares is anticipated to be $10.00, plus interest. Nevertheless, the Company cannot assure you that the per share distribution from the trust account, if the Company liquidates, will not be less than $10.00, plus interest, due to unforeseen claims of creditors.
Under the Delaware General Corporation Law (the “DGCL”), stockholders may be held liable for claims by third parties against a corporation to the extent of distributions received by them in a dissolution. If the corporation complies with certain procedures set forth in Section 280 of the DGCL intended to ensure that it makes reasonable provision for all claims against it, including a 60-day notice period during which any third-party claims can be brought against the corporation, a 90-day period during which the corporation may reject any claims brought, and an additional 150-day waiting period before any liquidating distributions are made to stockholders, any liability of stockholders with respect to a liquidating distribution is limited to the lesser of such stockholder’s pro rata share of the claim or the amount distributed to the stockholder, and any liability of the stockholder would be barred after the third anniversary of the dissolution. However, because the Company will not be complying with Section 280 of the DGCL, Section 281(b) of the DGCL requires us to adopt a plan, based on facts known to us at such time that will provide for our payment of all existing and pending claims or claims that may be potentially brought against us within the subsequent ten years. Because we are a blank check company, rather than an operating company, and our operations have been and will continue to be limited to searching for prospective target businesses to acquire, the only likely claims to arise would be from our vendors (such as lawyers, investment bankers, etc.) or prospective target businesses.
If the Extension Amendment Proposal is approved and the Extension is implemented, the Company will (i) remove from the trust account an amount (the “Withdrawal Amount”) equal to the pro rata portion of funds available in the trust account relating to the converted public shares and (ii) deliver to the holders of such converted public shares their pro rata portion of the Withdrawal Amount. The remainder of such funds, plus the Deposits or Contributions, shall remain in the trust account and be available for use by the Company to complete an initial business combination on or before the Extended Date. Holders of public

6


shares who do not convert their public shares now will retain their conversion rights and their ability to vote on an initial business combination through the Extended Date if the Extension Amendment Proposal is approved and the Extension is implemented.
The record date for the special meeting is December 31, 2021. Record holders of shares of the Company’s common stock at the close of business on the record date are entitled to vote or have their votes castbe voted at the specialannual meeting. On the record date, there were 23,650,000 outstanding shares of Company

What vote is required to approve each item?

The vote required to elect our two Class A Common Stock, including 23,000,000 outstanding public shares and 5,750,000 shares of Company Class B Common Stock. The Company’s warrants do not have voting rights.

This proxy statement contains important information about the special meeting and the proposals. Please read it carefully and vote your shares.
This proxy statement is dated January 4, 2022 and is first being mailed to stockholders on or about that date.

7


QUESTIONS AND ANSWERS ABOUT THE SPECIAL MEETING
These Questions and Answers are only summaries of the matters they discuss. They do not contain all of the information that may be important to you. You should read carefully the entire document, including the annexes to this proxy statement.
Q.
Why am I receiving this proxy statement?
A. The Company is a blank check company formed in December 2019 for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. In August 2020, the Company consummated its IPO from which it derived gross proceeds of $230,000,000 (including $30,000,000 from the exercise of the underwriters’ over-allotment option). Like most blank check companies, our charter provides for the return of the IPO proceeds held in the trust account to the holders of public shares if there is no qualifying business combination(s) consummated on or before a certain date (in our case, February 18, 2022).
On July 11, 2021, the Company entered into the MIPA with Opco, the MSP Purchased Companies (as defined in the MIPA), the Members, and the Members’ Representative. Pursuant to the MIPA, and in connection with the Business Combination, the Members will sell and assign all of their membership interests in MSP to Opco in exchange for Up-C Units or, pursuant to notice delivered to the Company, with respect to all or a portion of the Up-C Units to be received by each such Member, one share of Class A Common Stock in lieu of each Up-C Unit.
This proxy statement relates to a special meeting of the stockholders to vote on the Extension Amendment Proposal. The purpose of the Extension Amendment Proposal and, if necessary, the Adjournment Proposal, is to allow the Company more time to complete an initial business combination. There may not be sufficient time to consummate the proposed Business Combination with MSP by February 18, 2022. Accordingly, the Company’s board of directors has determined that it is in the best interests of the Company’s stockholders to extend the date by which the Company has to consummate an initial business combination to the Extended Date. Notwithstanding stockholder approval of the Extension Amendment Proposal, the Company intends to consummate the Business Combination as soon as practicable.
Q.
What is being voted on?
A. You are being asked to vote on

a proposal to amend the Company’s charter to extend the date by which the Company has to consummate an initial business combination to the Extended Date; and

a proposal to approve the adjournment of the Special Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of the Extension Amendment Proposal.
Approval of the Extension Amendment Proposal is a condition to the implementation of the Extension.

8


If the Extension is implemented, the Company will remove the Withdrawal Amount from the trust account, deliver to the holders of converted public shares the pro rata portion of the Withdrawal Amount and retain the remainder of the funds in the trust account, plus the Deposits or Contributions, for the Company’s use in connection with consummating an initial business combination on or before the Extended Date.
We will not proceed if we do not have at least $5,000,001 of net tangible assets following approval of the Extension Amendment Proposal, after taking into account the Conversion.
If the Extension Amendment Proposal is approved and the Extension is implemented, the removal of the Withdrawal Amount from the trust account will reduce the Company’s net asset value. The Company cannot predict the amount that will remain in the trust account if the Extension Amendment Proposal is approved and the amount remaining in the trust account may be only a small fraction of the approximately $230.0 million that was in the trust account as of the record date. In such event, the Company may need to obtain additional funds to complete an initial business combination and there can be no assurance that such funds will be available on terms acceptable to the parties or at all.
If the Extension Amendment Proposal is not approved and we do not consummate an initial business combination by February 18, 2022, we will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter subject to lawfully available funds therefor, redeem 100% of the outstanding public shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including any interest but net of taxes payable, divided by the number of then outstanding public shares, which redemption will completely extinguish public stockholders�� rights as stockholders (including the right to receive further liquidation distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of our remaining stockholders and our board of directors, dissolve and liquidate, subject (in the case of (ii) and (iii) above) to our obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law.
The holders of the founder shares and private shares have waived their rights to participate in any liquidation distribution with respect to such shares. There will be no distribution from the trust account with respect to our warrants, which will expire worthless in the event we wind up. The Company will pay the costs of liquidation from its remaining assets outside of the trust account. If such funds are insufficient, the Sponsor has agreed to advance it the funds necessary to complete such liquidation (currently anticipated to be no more than approximately $15,000) and has agreed not to seek repayment of such expenses.
Q.
Why is the Company proposing the Extension Amendment Proposal?
A. The Company’s charter provided for the return of the IPO proceeds held in the trust account to the holders of public shares if there is no qualifying business combination(s) consummated on or before February 18, 2022.

9


On July 11, 2021, the Company entered into the MIPA with Opco, the MSP Purchased Companies (as defined in the MIPA), the Members, and the Members’ Representative. Pursuant to the MIPA, and in connection with the Business Combination, the Members will sell and assign all of their membership interests in MSP to Opco in exchange for Up-C Units or, pursuant to notice delivered to the Company, with respect to all or a portion of the Up-C Units to be received by each such Member, one share of Class A Common Stock in lieu of each Up-C Unit.
The purpose of the Extension Amendment Proposal and, if necessary, the Adjournment Proposal, is to allow the Company more time to complete an initial business combination. There may not be sufficient time to consummate the proposed Business Combination with MSP by February 18, 2022. Accordingly, the Company’s board of directors has determined that it is in the best interests of the Company’s stockholders to extend the date by which the Company has to consummate an initial business combination to the Extended Date. Notwithstanding stockholder approval of the Extension Amendment Proposal, the Company intends to consummate the Business Combination as soon as practicable.
The Company believes that given the Company’s expenditure of time, effort and money on the Business Combination, circumstances warrant providing public stockholders an opportunity to consider the Business Combination. Accordingly, the Company’s board of directors is proposing the Extension Amendment Proposal to extend the Company’s corporate existence until the Extended Date.
You are not being asked to vote on any proposed business combination at this time. If the Extension is implemented and you do not elect to convert your public shares now, you will retain the right to vote on any proposed business combination when and if one is submitted to stockholders and the right to convert your public shares into a pro rata portion of the trust account in the event a proposed business combination is approved and completed or the Company has not consummated an initial business combination by the Extended Date.
Q.
Why should I vote for the Extension Amendment Proposal?
A. The Company’s board of directors believes stockholders will benefit from the Company consummating the Business Combination and is proposing the Extension Amendment Proposal to extend the date by which the Company has to complete an initial business combination until the Extended Date and to allow for the Conversion. The Extension would give the Company additional time to complete an initial business combination.
Given the Company’s expenditure of time, effort and money on the Business Combination, circumstances warrant providing public stockholders an opportunity to consider the Business Combination, inasmuch as the Company is also affording stockholders who wish to convert their public shares as originally contemplated, the opportunity to do so as well. Accordingly, we believe that the Extension is consistent with the spirit in which the Company offered its securities to the public.
Q.
Why should I vote for the Adjournment Proposal?
A. If the Adjournment Proposal is not approved by the Company’s stockholders, the Company’s board of directors may not be able to adjourn the special meeting to a later date in the event that there are insufficient votes for, or otherwise in connection with, the approval of the Extension Amendment Proposal.

10


Q.
How do the Company’s executive officers, directors and affiliates intend to vote their shares?
A. All of the Company’s directors, executive officers and their respective affiliates, as well as the Sponsor, are expected to vote any common stock over which they have voting control (including any public shares owned by them) in favor of the Extension Amendment Proposal and in favor of the Adjournment Proposal.
The holders of the founder shares and private shares are not entitled to convert such shares in connection with the Extension Amendment Proposal. On the record date, the 5,750,000 insider shares and 650,000 private shares represented approximately 21.8% of the Company’s issued and outstanding common stock.
Neither the Company’s Sponsor, directors or executive officers nor any of their respective affiliates beneficially owned any public shares as of the record date. However, they may choose to buy public shares in the open market and/or through negotiated private purchases after the date of this proxy statement. In the event that purchases do occur, the purchasers may seek to purchase shares from stockholders who would otherwise have voted against the Extension Amendment Proposal and/or elected to convert their shares. Any public shares so purchased will be voted in favor of the Extension Amendment Proposal and the Adjournment Proposal.
Q.
What vote is required to adopt each proposal?
A. Extension Amendment Proposal. Approval of the Extension Amendment Proposal will require the affirmative vote of holders of at least 65% of the issued and outstanding shares of the Company’s common stock as of the record date.
Adjournment Proposal. Approval of the Adjournment Proposal will require the affirmative vote of the holders of the majority of the issued and outstanding shares of the Company’s common stock represented in person or by proxy at the special meeting and entitled to vote thereon.
Q.
What if I don’t want to vote for the Extension Amendment Proposal or the Adjournment Proposal?
A. If you do not want the Extension Amendment Proposal to be approved, you must abstain, not vote, or vote against the proposal. If the Extension Amendment Proposal is approved, and the Extension is implemented, then the Withdrawal Amount will be withdrawn from the trust account and paid to the converting or non-voting holders.
If you do not want the Adjournment Proposal to be approved, you must abstain, not vote or vote against the proposal.
Q.
Will you seek any further extensions to liquidate the trust account?
A. Other than the extension until the Extended Date as described in this proxy statement, the Company does not currently anticipate seeking any further extension to consummate an initial business combination, although it may determine to do so in the future.

11


Q.
What happens if the Extension Amendment Proposal is not approved?
A. If the Extension Amendment Proposal is not approved and we do not consummate an initial business combination by February 18, 2022, we will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter subject to lawfully available funds therefor, redeem 100% of the outstanding public shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including any interest but net of taxes payable, divided by the number of then outstanding public shares, which redemption will completely extinguish public stockholders’ rights as stockholders (including the right to receive further liquidation distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of our remaining stockholders and our board of directors, dissolve and liquidate, subject (in the case of (ii) and (iii) above) to our obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law.
The holders of the founder shares and private shares waived their rights to participate in any liquidation distribution with respect to such shares. There will be no distribution from the trust account with respect to our warrants which will expire worthless in the event we wind up. The Company will pay the costs of liquidation from its remaining assets outside of the trust account, which it believes are sufficient for such purposes. If such funds are insufficient, the Sponsor has agreed to advance the Company the funds necessary to complete such liquidation (currently anticipated to be no more than approximately $15,000) and has agreed not to seek repayment of such expenses.
Q.
If the Extension Amendment Proposal is approved, what happens next?
A. If the Extension Amendment Proposal is approved, the Company will continue to attempt to consummate an initial business combination until the Extended Date or the earlier date on which the Company’s board of directors otherwise determines in its sole discretion that it will not be able to consummate an initial business combination by the Extended Date and does not wish to seek an additional extension.
The Company will remain a reporting company under the Securities Exchange Act of 1934 and its units, common stock and warrants will remain publicly traded until the Extended Date.
If the Extension Amendment Proposal is approved, the removal of the Withdrawal Amount from the trust account will reduce the amount remaining in the trust account and increase the percentage interest of Company shares held by the Company’s officers, directors and their affiliates.
Q.
Would I still be able to exercise my conversion rights if I vote against any subsequently proposed business combination?
A. Unless you elect to convert your shares, you will be able to vote on any subsequently proposed business combination when it is submitted to stockholders. If you disagree with the business combination, you will retain your right to vote against it and/or convert your public shares upon consummation of the business combination in connection with the stockholder vote to approve such business combination, subject to any limitations set forth in the charter.

12


Q.
How do I attend the special meeting?
A. You will need your control number for access. If you do not have your control number, contact Continental Stock Transfer & Trust Company at the phone number or e-mail address below. Beneficial investors who hold shares through a bank, broker or other intermediary, will need to contact them and obtain a legal proxy. Once you have your legal proxy, contact Continental Stock Transfer & Trust Company to have a control number generated. Continental Stock Transfer & Trust Company contact information is as follows: 917-262-2373, or email proxy@continentalstock.com.
Q.
How do I change my vote?
A. If you have submitted a proxy to vote your shares and wish to change your vote, you may do so by delivering a later-dated, signed proxy card to the Company’s secretary prior to the date of the special meeting or by attending the special meeting online and voting. Attendance at the special meeting alone will not change your vote. You also may revoke your proxy by sending a notice of revocation to the Company located at 4218 NE 2nd Avenue, Miami, Florida 33137.
Q.
How are votes counted?
A. Votes will be counted by the inspector of election appointed for the special meeting, who will separately count “FOR” and “AGAINST” votes, abstentions and broker non-votes. The Extension Amendment Proposal must be approved by the affirmative vote of at least 65% of the issued and outstanding shares of common stock as of the record date. The Adjournment Proposal must be approved by the affirmative vote of the majority of the issued and outstanding shares of the Company’s common stock represented in person or by proxy at the special meeting and entitled to vote thereon.
With respect to the Extension Amendment Proposal, abstentions and broker non-votes will have the same effect as “AGAINST” votes. Abstentions and broker non-votes will not have any effect on the Adjournment Proposal. If your shares are held by your broker as your nominee (that is, in “street name”), you may need to obtain a proxy form from the institution that holds your shares and follow the instructions included on that form regarding how to instruct your broker to vote your shares. If you do not give instructions to your broker, your broker can vote your shares with respect to “discretionary” items, but not with respect to “non-discretionary” items. Discretionary items are proposals considered routine under the rules of the New York Stock Exchange applicable to member brokerage firms. These rules provide that for routine matters your broker has the discretion to vote shares held in street name in the absence of your voting instructions. On non-discretionary items for which you do not give your broker instructions, the shares will be treated as broker non-votes.
Q.
If my shares are held in “street name,” will my broker automatically vote them for me?
A. No. Your broker can vote your shares only if you provide instructions on how to vote. You should instruct your broker to vote your shares. Your broker can tell you how to provide these instructions.
Q.
What is a quorum requirement?
A. A quorum of stockholders is necessary to hold a valid meeting. A quorum will be present if at least a majority of the outstanding shares of common stock on the record date are represented by stockholders present at the special meeting or by proxy.

13


Your shares will be counted towards the quorum only if you submit a valid proxy (or one is submitted on your behalf by your broker, bank or other nominee) or if you vote in person at the special meeting. Abstentions and broker non-votes will be counted towards the quorum requirement. If there is no quorum, a majority of the votes present at the special meeting may adjourn the special meeting to another date.
Q.
Who can vote at the special meeting?
A. Only holders of record of the Company’s common stock at the close of business on December 31, 2021 are entitled to have their vote counted at the special meeting and any adjournments or postponements thereof. On the record date, 29,400,000 shares of common stock were outstanding and entitled to vote, including 23,650,000 shares of Class A Common Stock and 5,750,000 shares of Class B Common Stock.
Stockholder of Record: Shares Registered in Your Name. If on the record date your shares were registered directly in your name with the Company’s transfer agent, Continental Stock Transfer & Trust Company, then you are a stockholder of record. As a stockholder of record, you may vote in person at the special meeting or vote by proxy. Whether or not you plan to attend the special meeting in person, we urge you to fill out and return the enclosed proxy card to ensure your vote is counted.
Beneficial Owner: Shares Registered in the Name of a Broker or Bank. If on the record date your shares were held, not in your name, but rather in an account at a brokerage firm, bank, dealer, or other similar organization, then you are the beneficial owner of shares held in “street name” and these proxy materials are being forwarded to you by that organization. As a beneficial owner, you have the right to direct your broker or other agent on how to vote the shares in your account. You are also invited to attend the special meeting. However, since you are not the stockholder of record, you may not vote your shares in person at the special meeting unless you request and obtain a valid proxy from your broker or other agent.
Q.
Does the board recommend voting for the approval of the Extension Amendment Proposal and the Adjournment Proposal?
A. Yes. After careful consideration of the terms and conditions of these proposals, the board of directors of the Company has determined that the Extension Amendment and, if presented, the Adjournment Proposal are fair to and in the best interests of the Company and its stockholders. The board of directors recommends that the Company’s stockholders vote “FOR” the Extension Amendment Proposal and the Adjournment Proposal.
Q.
What interests do the Company’s directors and officers have in the approval of the proposals?
A. The Company’s directors, officers and their affiliates have interests in the proposals that may be different from, or in addition to, your interests as a stockholder. These interests include, but are not limited to, beneficial ownership of founder shares and private shares and warrants that will become worthless if the Extension Amendment Proposal is not approved, loans by them that will not be repaid in the event of our winding up and the possibility of future compensatory arrangements. See the section entitled “The Special Meeting — Interests of the Company’s Directors and Officers.”
Q.
What if I object to the Extension Amendment Proposal? Do I have appraisal rights?
A. Company stockholders do not have appraisal rights in connection with the Extension Amendment Proposal under the DGCL.

14


Q.
What happens to the Company’s warrants if the Extension Amendment Proposal is not approved?
A. If the Extension Amendment Proposal is not approved and we do not consummate an initial business combination by February 18, 2022, we will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter subject to lawfully available funds therefor, redeem 100% of the outstanding public shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including any interest but net of taxes payable, divided by the number of then outstanding public shares, which redemption will completely extinguish public stockholders’ rights as stockholders (including the right to receive further liquidation distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of our remaining stockholders and our board of directors, dissolve and liquidate, subject (in the case of (ii) and (iii) above) to our obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law. In such event, your warrants will become worthless.
Q.
What happens to the Company’s warrants if the Extension Amendment Proposal is approved?
A. If the Extension Amendment Proposal is approved, the Company will continue to attempt to consummate an initial business combination until the Extended Date. The warrants will remain outstanding in accordance with their terms during any extension period. The warrants will still become exercisable commencing on the consummation of any business combination.
Q.
What do I need to do now?
A. The Company urges you to read carefully and consider the information contained in this proxy statement, including the annexes, and to consider how the proposals will affect you as a Company stockholder. You should then vote as soon as possible in accordance with the instructions provided in this proxy statement and on the enclosed proxy card.
Q.
How do I vote?
A. If you are a holder of record of our common stock, you may vote online at the special meeting or by submitting a proxy for the special meeting. Whether or not you plan to attend the special meeting online, we urge you to vote by proxy to ensure your vote is counted. You may submit your proxy by completing, signing, dating and returning the enclosed proxy card in the accompanying pre-addressed postage paid envelope. You may still attend the special meeting and vote online if you have already voted by proxy.
If your shares of our common stock are held in “street name” by a broker or other agent, you have the right to direct your broker or other agent on how to vote the shares in your account. You are also invited to attend the special meeting. However, since you are not the stockholder of record, you may not vote your shares online at the special meeting unless you request and obtain a valid proxy from your broker or other agent.
Q.
How do I convert my shares of Company common stock?
A. If the Extension is implemented, each public stockholder may seek to convert his public shares for a pro rata portion of the funds available in the trust account, less any taxes we anticipate will be owed on such funds but have not yet been paid. Holders of public shares do not need to vote on the Extension Amendment Proposal or be a holder of record on the record date to exercise conversion rights.

15


To demand conversion, you must either physically tender your stock certificates to Continental Stock Transfer & Trust Company, the Company’s transfer agent, at Continental Stock Transfer & Trust Company, 1 State Street, New York, New York 10004, Attn: Mark Zimkind, mzimkind@continentalstock.com, no later than two business days prior to the vote for the Extension Amendment Proposal or deliver your shares to the transfer agent electronically using The Depository Trust Company’s DWAC (Deposit/Withdrawal At Custodian) System, which election would likely be determined based on the manner in which you hold your shares. You will only be entitled to receive cash in connection with a conversion of these shares if you continue to hold them until the effective date of the Extension.
Q.
What should I do if I receive more than one set of voting materials?
A. You may receive more than one set of voting materials, including multiple copies of this proxy statement and multiple proxy cards or voting instruction cards, if your shares are registered in more than one name or are registered in different accounts. For example, if you hold your shares in more than one brokerage account, you will receive a separate voting instruction card for each brokerage account in which you hold shares. Please complete, sign, date and return each proxy card and voting instruction card that you receive in order to cast a vote with respect to all of your Company shares.
Q.
Who is paying for this proxy solicitation?
A. The Company will pay for the entire cost of soliciting proxies. In addition to these mailed proxy materials, our directors and officers may also solicit proxies in person, by telephone or by other means of communication. These parties will not be paid any additional compensation for soliciting proxies. We may also reimburse brokerage firms, banks and other agents for the cost of forwarding proxy materials to beneficial owners.
Q.
Who can help answer my questions?
A. If you have questions about the proposals or if you need additional copies of the proxy statement or the enclosed proxy card you should contact:
Lionheart Acquisition Corporation II
4218 NE 2nd Avenue
Miami, Florida 33137
Attn: Paul Rapisarda
Telephone: (305) 573-3900
or
MacKenzie Partners, Inc.
1407 Broadway
New York, New York 10018
Toll Free Telephone: (800) 322-2885
Main Telephone: (212) 929-5500
E-mail: proxy@mackenziepartners.com
You may also obtain additional information about the Company from documents filed with the SEC by following the instructions in the section entitled “Where You Can Find More Information.”

16


FORWARD-LOOKING STATEMENTS
Some of the statements containedI directors named in this proxy statement, constitute forward-looking statements withineach for a three-year term expiring at the meaning2026 Annual Meeting or until their successors are duly elected and qualified, is a plurality of the federal securities laws. Forward-looking statements relate to expectations, beliefs, projections, future plans and strategies, anticipated events or trends and similar expressions concerning matters that are not historical facts. Forward-looking statements reflect our current views with respect to, among other things, the pending business combination, our capital resources and results of operations. Likewise, our financial statements and all of our statements regarding market conditions and results of operations are forward-looking statements. In some cases, you can identify these forward-looking statements by the use of terminology such as “outlook,” “believes,” “expects,” “potential,” “continues,” “may,” “will,” “should,” “could,” “seeks,” “approximately,” “predicts,” “intends,” “plans,” “estimates,” “anticipates” or the negative version of these words or other comparable words or phrases.
The forward-looking statements contained in this proxy statement reflect our current views about future events and are subject to numerous known and unknown risks, uncertainties, assumptions and changes in circumstances that may cause its actual results to differ significantly from those expressed in any forward-looking statement. We do not guarantee that the transactions and events described will happen as described (or that they will happen at all). The following factors, among others, could cause actual results and future events to differ materially from those set forth or contemplated in the forward-looking statements:

our ability to complete the business combination;

the anticipated benefitsvotes of the business combination;

shares of Common Stock cast at the volatilityAnnual Meeting. The vote required for the ratification of the market price and liquidityselection of Deloitte as our securities;

the use of funds not held in the trust account; and

the competitive environment in which our successor will operate following the business combination.
While forward-looking statements reflect our good faith beliefs, they are not guarantees of future performance. We disclaim any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, new information, data or methods, future events or other changes after the date of this proxy statement, except as required by applicable law. For a further discussion of these and other factors that could cause our future results, performance or transactions to differ significantly from those expressed in any forward-looking statement, please see the section entitled “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2020, as filed with the SEC on March 31, 2021 and in other reports we file with the SEC. You should not place undue reliance on any forward-looking statements, which are based only on information currently available to us (or to third parties making the forward-looking statements).

17


BACKGROUND
The Company
We are a Delaware company incorporated on December 20, 2019 for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.
In August 2020, we consummated our IPO of 23,000,000 units, including 3,000,000 units that were subject to the underwriters’ over-allotment option, with each unit consisting of one share of common stock and one-half of one redeemable warrant, with each whole warrant entitling the holder to purchase one share of common stock. The units were sold at an offering price of $10.00 per unit, generating gross proceeds of $230,000,000.
Prior to our IPO, we issued an aggregate of 5,000,000 founder shares for an aggregate purchase price of $25,000. Subsequently, in February 2020, we declared a dividend of 0.15 share for each outstanding share, resulting in 5,750,000 shares being issued and outstanding.
Simultaneous with the consummation of the IPO, we consummated the private placement of an aggregate of 650,000 private placement units at a price of $10.00 per private placement unit, generating total proceeds of $6,500,000.
The prospectus for our IPO and our charter originally provided that we had only until February 18, 2022 to complete an initial business combination. As of the record date, the Company had approximately $230.0 million of cash in the trust account.
On July 11, 2021, the Company entered into the MIPA with Opco, the MSP Purchased Companies (as defined in the MIPA), the Members, and the Members’ Representative. Pursuant to the MIPA, and in connection with the Business Combination, the Members will sell and assign all of their membership interests in MSP to Opco in exchange for Up-C Units or, pursuant to notice delivered to the Company, with respect to all or a portion of the Up-C Units to be received by each such Member, one share of Class A Common Stock in lieu of each Up-C Unit.
The mailing address of the Company’s principal executive officeauditor is 4218 NE 2nd Avenue, Miami, Florida 33137, and its telephone number is +1 (305) 573-3900.

18


THE EXTENSION AMENDMENT PROPOSAL AND THE ADJOURNMENT PROPOSAL
The Extension Amendment Proposal
The Company is proposing to amend its charter to extend the date by which the Company has to consummate an initial business combination to the Extended Date. The Extension Amendment Proposal is essential to the overall implementation of the board of directors’ plan to allow the Company more time to complete the Business Combination. Approval of the Extension Amendment Proposal is a condition to the implementation of the Extension. A copy of the proposed amendment to the charter of the Company is attached to this proxy statement as Annex A.
All holders of the Company’s public shares, whether they vote for or against the Extension Amendment Proposal or do not vote at all, will be permitted to convert all or a portion of their public shares into their pro rata portion of the trust account, provided that the Extension is implemented. Holders of public shares do not need to be a holder of record on the record date in order to exercise conversion rights. We will not proceed with the Extension if we do not have at least $5,000,001 of net tangible assets following approval of the Extension Amendment \Proposal, after taking into account the Conversion.
The per-share pro rata portion of the trust account on the record date (which is expected to be the same approximate amount two business days prior to the special meeting) was approximately $10.00. The closing price of the Company’s common stock on the record date was $9.96. Accordingly, if the market price were to remain the same until the date of the special meeting, exercising conversion rights would result in a public stockholder receiving approximately $0.04 more than if he sold his stock in the open market. The Company cannot assure stockholders that they will be able to sell their shares of Company common stock in the open market, even if the market price per share is higher than the conversion price stated above, as there may not be sufficient liquidity in its securities when such stockholders wish to sell their shares.
The Company has agreed that if the Extension Amendment Proposal is approved and the Extension is implemented, it will make the Deposit of $0.0333 for each public share that is not converted in connection with the stockholder vote to approve the Extension, for each monthly period, or portion thereof, that is needed by the Company to complete an initial business combination from and after February 18, 2022 and through and including the earlier to occur of (i) consummation of the Company’s initial business combination and (ii) the Extended Date. Alternatively, if the Company does not have the funds necessary to make the Deposit referred to above, the Sponsor has agreed that it and/or any of its affiliates or designees will make the Contribution of $0.0333 for each public share that is not converted in connection with the stockholder vote to approve the Extension, for each monthly period, or portion thereof, that is needed by the Company to complete an initial business combination from and after February 18, 2022 and through and including the earlier to occur of (i) consummation of the Company’s initial business combination and (ii) the Extended Date. Accordingly, if the Company takes until the Extended Date to complete an initial business combination, which would represent six (6) monthly periods through the Extended Date, the Company or Sponsor would make Deposits or Contributions of $765,900 per month, or an aggregate of $4,595,400 (assuming no public shares were converted). Each Deposit or Contribution will be placed in the trust account within two business days prior to the beginning of the applicable monthly period (or portion thereof), other than the first Deposit or Contribution which will be made on the day of the approval and implementation of the Extension Amendment Proposal. Accordingly, if the Extension Amendment Proposal is approved and the Extension is implemented and the Company takes the full time through the Extended Date to complete an initial business combination, the conversion amount per share at the special meeting for such initial business combination or the Company’s subsequent liquidation will be approximately $10.20 per share (without taking into account any interest), in comparison to the current conversion amount of approximately $10.00 per share. The Company and Sponsor will not make any Deposit or Contribution unless the Extension Amendment Proposal is approved and the Extension is granted. The Contributions will not bear any interest and will be repayable by the Company to the Sponsor or its affiliates upon consummation of an initial business combination. The loans will be forgiven if the Company is unable to consummate an initial business combination except to the extent of any funds held outside of the trust account. The Company or Sponsor, as applicable, will have the sole discretion whether to continue extending for additional monthly periods until the Extended Date and if the Company or Sponsor, as applicable, determine not to continue extending for additional monthly periods, their obligation to make additional Deposits or Contributions will

19


terminate. If this occurs, or if the Company’s board of directors otherwise determines that the Company will not be able to consummate an initial business combination by the Extended Date and does not wish to seek an additional extension, the Company would wind up the Company’s affairs and redeem 100% of the outstanding public shares in accordance with the same procedures set forth below that would be applicable if the Extension Amendment Proposal is not approved.
The Adjournment Proposal
The Adjournment Proposal, if adopted, will allow the Company’s board of directors to adjourn the special meeting to a later date or dates to permit further solicitation of proxies. The Adjournment Proposal will only be presented to the Company’s stockholders in the event that there are insufficient votes for, or otherwise in connection with, the approval of the Extension Amendment Proposal. In no event will the Company’s board of directors adjourn the Special Meeting beyond February 18, 2022.
If the Adjournment Proposal is not approved by the Company’s stockholders, the Company’s board of directors may not be able to adjourn the special meeting to a later date in the event that there are insufficient votes for, or otherwise in connection with, the approval of the Extension Amendment Proposal.
The approval of the Adjournment Proposal requires the affirmative vote of thea majority of the votes cast by stockholders represented in person or by proxy at the special meeting. Accordingly, if a valid quorum is otherwise established, a stockholder’s failure to vote by proxy or onlineAnnual Meeting.

The inspector of election for the Annual Meeting shall determine the number of shares of Common Stock represented at the special meeting, the existence of a quorum and the validity and effect of proxies, and shall count and tabulate ballots and votes and determine the results thereof. Proxies received but marked as abstentions and broker non-votes will be included in the calculation of the number of shares considered to be present at the meeting for purposes of determining a quorum.

A “broker non-vote” will occur when a nominee holding shares for a beneficial owner does not vote on a particular proposal because the nominee does not have no effectdiscretionary power with respect to that proposal and has not received instructions from the beneficial owner. Broker non-votes will not be counted as votes cast for the election of directors, and thus will not have any impact on the outcomeresults of anysuch elections. On other matters submitted for a vote, onincluding the Adjournment Proposal. Abstentionsratification of the selection of Deloitte as our auditor, broker non-votes will not be counted as votes cast, and abstentions will be counted in connection with the determination of whethertreated as a valid quorum is established but will have no effect on the outcomevote “against.” If less than a majority of the Adjournment Proposal.

Reasons for the Proposals
The Company’s IPO prospectus and charter provided that the Company had until February 18, 2022 to complete an initial business combination.
The Company believes that given the Company’s expenditure of time, effort and money on the Business Combination, circumstances warrant providing public stockholders an opportunity to consider a proposed business combination. Accordingly, since the Company may not be able to complete the Business Combination with MSP by February 18, 2022, the Company has determined to seek stockholder approval to extend the time for closing an initial business combination beyond February 18, 2022 to the Extended Date. The Company and its officers and directors agreed that it would not seek to amend the Company’s charter to allow for a longer period of time to complete an initial business combination unless it provided holders of public shares with the right to seek conversion of their public shares in connection therewith.
The purpose of the Adjournment Proposal is to allow the Company’s board of directors to adjourn the special meeting to a later date or dates to permit further solicitation of proxies.
If the Extension Amendment Proposal Is Not Approved
If the Extension Amendment Proposal is not approved and we do not consummate an initial business combination by February 18, 2022, we will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter subject to lawfully available funds therefor, redeem 100%combined voting power of the outstanding public


shares of Common Stock is represented at the Annual Meeting, a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including any interest but net of taxes payable, divided by the number of then outstanding public shares, which redemption will completely extinguish public stockholders’ rights as stockholders (including the right to receive further liquidation distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of our remaining stockholders and our board of directors, dissolve and liquidate, subject (in the case of (ii) and (iii) above) to our obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law.

If the Extension Amendment Proposal is not approved, the Company or Sponsor, as applicable, will not make the Deposit or Contribution, as applicable.

20


The holdersmajority of the founder shares and private shares have waived their rightsso represented may adjourn the Annual Meeting from time to participate in any liquidation distribution with respecttime without further notice.

What are the Board’s recommendations?

As more fully discussed under Summary of Matters to such shares. There will be no distribution fromVoted On, our Board of Directors recommends a vote FOR the trust account with respect to the Company’s warrants which will expire worthless in the event the Extension Amendment Proposal is not approved. The Company will pay the costs of liquidation from its remaining assets outsidere-election of the trust account. If such funds are insufficient,two Class I director nominees named in this proxy statement; and a vote FOR the Sponsor has agreed to advance it the funds necessary to complete such liquidation (currently anticipated to be no more than approximately $15,000) and has agreed not to seek repayment of such expenses.

If the Extension Amendment Proposal is Approved
If the Extension Amendment Proposal is approved, the Company will file an amendment to the charter with the Secretary of Stateratification of the Stateselection of Delaware in the form of Annex A hereto to extend the time it has to complete an initial business combination until the Extended Date. The Company will then continue to attempt to consummate an initial business combination until the Extended Date. The Company will remain a reporting company under the Securities Exchange Act of 1934 and its units, common stock and warrants will remain publicly traded during the extension period. The warrants will continue in existence in accordance with their terms.
Deloitte as auditor.

YouUnless contrary instructions are not being asked to vote on any business combination at this time. If the Extension is implemented and you do not elect to convert your public shares now, you will retain the right to vote on any proposed business combination when and if it is submitted to stockholders and the right to convert your public shares into a pro rata portion of the trust account in the event the proposed business combination is approved and completed or if the Company has not consummated an initial business combination by the Extended Date.

If the Extension Amendment Proposal is approved, and the Extension is implemented, the removal of the Withdrawal Amount from the trust account will reduce the Company’s net asset value. The Company cannot predict the amount that will remain in the trust account if the Extension Amendment Proposal is approved, and the amount remaining in the trust account may be only a small fraction of the approximately $230.0 million that was in the trust account as of the record date. However, we will not proceed if we do not have at least $5,000,001 of net tangible assets following approval of the Extension Amendment Proposal (after taking into account the conversion of public shares).
Conversion Rights
If the Extension Amendment Proposal is approved, and the Extension is implemented, each public stockholder may seek to convert his public shares for a pro rata portion of the funds available in the trust account, less any taxes we anticipate will be owed on such funds but have not yet been paid, calculated as of two business days prior to the special meeting. Holders of public shares do not need to voteindicated on the Extension Amendment Proposal or be a holder of record on the record dateenclosed proxy, all shares represented by valid proxies received pursuant to exercise conversion rights.
TO DEMAND CONVERSION, YOU MUST EITHER PHYSICALLY TENDER YOUR STOCK CERTIFICATES TO CONTINENTAL STOCK TRANSFER & TRUST COMPANY, THE COMPANY’S TRANSFER AGENT, AT CONTINENTAL STOCK TRANSFER & TRUST COMPANY, 1 STATE STREET, NEW YORK, NEW YORK 10004, ATTN: MARK ZIMKIND, MZIMKIND@CONTINENTALSTOCK.COM, NO LATER THAN TWO BUSINESS DAYS PRIOR TO THE VOTE FOR THE EXTENSION AMENDMENT PROPOSAL OR DELIVER YOUR SHARES TO THE TRANSFER AGENT ELECTRONICALLY USING THE DEPOSITORY TRUST COMPANY’S DWAC (DEPOSIT/WITHDRAWAL AT CUSTODIAN) SYSTEM.
You will only be entitled to receive cash in connection with a conversion of these shares if you continue to hold them until the effective date of the Extension and Conversion. The requirement for physical or electronic delivery prior to the vote at the special meeting ensures that a converting holder’s election is irrevocable once the Extension Amendment Proposal is approved. In furtherance of such irrevocable election, stockholders making the election will not be able to tender their shares after the vote at the special meeting.
The electronic delivery process through the DWAC system can be accomplished by the stockholder, whether or not it is a record holder or its shares are held in “street name,” by contacting the transfer agent or its broker and requesting delivery of its shares through the DWAC system. Delivering shares physically may

21


take significantly longer. In order to obtain a physical stock certificate, a stockholder’s broker and/or clearing broker, DTC, and the Company’s transfer agent will need to act together to facilitate this request. There is a nominal cost associated with the above-referenced tendering process and the act of certificating the shares or delivering them through the DWAC system. The transfer agent will typically charge the tendering broker a nominal amount and the broker would determine whether or not to pass this cost on to the redeeming holder. It is the Company’s understanding that stockholders should generally allot at least two weeks to obtain physical certificates from the transfer agent. The Company does not have any control over this process or over the brokers or DTC, and it may take longer than two weeks to obtain a physical stock certificate. Such stockholders will have less time to make their investment decision than those stockholders that deliver their shares through the DWAC system. Stockholders who request physical stock certificates and wish to convert may be unable to meet the deadline for tendering their shares before exercising their conversion rights and thus will be unable to convert their shares.
Certificates thatsolicitation (and which have not been tendered in accordance with these procedures prior to the vote for the Extension Amendment Proposal will not be converted into a pro rata portion of the funds held in the trust account. In the event that a public stockholder tenders its shares and decides prior to the vote at the special meeting that it does not want to convert its shares, the stockholder may withdraw the tender. If you delivered your shares for conversion to our transfer agent and decide prior to the vote at the special meeting not to convert your shares, you may request that our transfer agent return the shares (physically or electronically). You may make such request by contacting our transfer agent at address listed above. In the event that a public stockholder tenders shares and the Extension Amendment Proposal is not approved or is abandoned, these shares will be redeemedrevoked in accordance with the termsprocedures set forth below) will be voted (1) FOR the re-election of our two Class I director nominees named in this proxy statement; and (2) FOR the ratification of the charter promptly followingselection of Deloitte as auditor. In the special meeting, as described elsewhere herein. The Company anticipates thatevent a public stockholder who tenders shares for conversion in connection with the vote to approve the Extension Amendment Proposal would receive paymentspecifies a different choice by means of the conversion price forenclosed proxy, such shares soon after the completion of the Extension Amendment Proposal. The transfer agent will hold the certificates of public stockholders that make the election until such shares are converted for cash or redeemed in connection with our winding up.
If properly demanded, the Company will convert each public share for a pro rata portion of the funds available in the trust account, less any taxes we anticipate will be owed on such funds but have not yet been paid, calculated as of two business days prior to the special meeting. As of the record date, this would amount to approximately $10.00 per share (which is expected to be the same approximate amount as of two business days prior to the special meeting). The closing price of the Company’s common stock on the record date was $9.96. Accordingly, if the market price were to remain the same until the date of the special meeting, exercising conversion rights would result in a public stockholder receiving approximately $0.04 more than if he sold his stock in the open market. Additionally, if the Extension Amendment Proposal is approved and the Company or Sponsor make the Deposit or Contribution, the conversion price for any subsequent business combination or liquidation will be approximately $10.20, or $0.20 per share more than the current conversion price.
If you exercise your conversion rights, you will be exchanging your shares of the Company’s common stock for cash and will no longer own the shares. You will be entitled to receive cash for these shares only if you properly demand conversion by tendering your stock certificate(s) to the Company’s transfer agent prior to the vote for the Extension Amendment Proposal. If the Extension Amendment Proposal is not approved or if it is abandoned, these shares will be redeemedvoted in accordance with the termsspecification made.

How do I vote?

You can vote in any of the charter promptly following the special meeting as described elsewhere herein.


22


THE SPECIAL MEETING
Date, Time and Place.   The Special Meeting of the Company’s stockholders will be held at 11:00 a.m. Eastern Time on January 27, 2022 as a virtual meeting. You will be able to attend, voteways. Please check your shares and submit questions during the special meeting via a live webcast available at https://www.cstproxy.com/lionheartacquisitioncorpii/2022. The special meeting will be held virtually over the internet by means of a live audio webcast. Only stockholders who own shares of our common stock as of the close of business on the record date will be entitled to attend the virtual meeting.
To registerproxy card or contact your broker for the virtual meeting, please follow these instructions as applicable to the nature of your ownership of our common stock.
voting instructions.

If your shares are registered in your name with our transfer agent(as a stockholder of record):

To vote by Internet or telephone:Log on to the website or call the toll-free number set forth in the notice of meeting mailed to you and you wish to attendfollow the online-only virtual meeting, go to https://www.cstproxy.com/lionheartacquisitioncorpii/2022, enter the control numberinstructions.
To vote by mail:If you received ona printed copy of the proxy materials, complete, sign, date, and mail your proxy card in the enclosed, postage-prepaid envelope.
To vote during the meeting:Withdraw your earlier proxy and clickvote at the Annual Meeting via the Internet.

If your shares are held in “street name”:

You should give instructions to your broker on how to vote your shares. If you do not provide voting instructions to your broker, your broker has discretion to vote those shares on matters that are routine. However, a broker cannot vote shares on non-routine matters without your instructions. This is referred to as a “broker non-vote.” Under the rules of The Nasdaq Stock Market LLC (“Nasdaq”), the Director Election Proposal is non-routine and, as such, a broker does not have the discretion to vote on the “Click here” to preregister forDirector Election Proposal if such broker has not received instructions from the online meeting link at the topbeneficial owner of the page. Justshares represented. The Auditor Ratification Proposal is considered a routine proposal and may be voted in the absence of instructions.

Can I change my vote after I return my proxy card?

Yes. The giving of a proxy does not eliminate the right to vote in person should any stockholder giving the proxy so desire. Stockholders have an unconditional right to revoke their proxy at any time prior to the startexercise of the special meeting you will need to log back into the special meeting site using your control number. Pre-registration is recommended but is not required in order to attend.

Beneficial owners who wish to attend the online-only virtual meeting must obtain a legalthat proxy, by contacting their account representative at the bank, broker, or other nominee that holds their shares and e-mail a copy (a legible photograph is sufficient) of their legal proxy to proxy@continentalstock.com. Beneficial owners who e-mail a valid legal proxy will be issued a meeting control number that will allow them to register to attend and participate in the online-only meeting. After contacting our transfer agent a beneficial holder will receive an e-mail prior to the special meeting with a link and instructions for entering the virtual meeting. Beneficial stockholders should contact our transfer agent at least five business days prior to the special meeting date.
Voting Power; Record Date.   You will be entitled to vote or direct votes to be cast at the special meeting, if you owned Company common stock at the close of business on December 31, 2021, the record date for the special meeting. At the close of business on the record date, there were 29,400,000 outstanding shares of Company common stock each of which entitles its holder to cast one vote per proposal. Company warrants do not carry voting rights.
Proxies; Board Solicitation.   Your proxy is being solicited by the Company’s board of directors on the proposals being presented to stockholders at the special meeting. No recommendation is being made as to whether you should elect to convert your shares. Proxies may be solicited in person or by telephone. If you grant a proxy, you may still revoke your proxy and vote your shares in person at the special meeting. MacKenzie Partners, Inc. is assisting the Company inAnnual Meeting, by filing a written revocation or duly executed proxy bearing a later date with our Secretary at our headquarters.


Who pays for costs relating to the proxy solicitation process formaterials and Annual Meeting?

The costs of preparing, assembling, and mailing this special meeting. The Company will pay that firmProxy Statement, the Notice of Annual Meeting of Stockholders and the enclosed Annual Report and proxy card, along with the cost of posting the proxy materials on a minimum fee of $50,000 plus disbursements for such services at the closing of any proposed business combination.

Required Vote
The affirmative votewebsite, are to be borne by holders of at least 65% of the Company’s issued and outstanding common stock is required to approve the Extension Amendment Proposal, including holders of the founder shares and private shares. Abstentions and broker non-votes will have the same effect as “AGAINST” votes with respectus. In addition to the Extension Amendment Proposal. Alluse of the Company’smail, our directors, executive officers, and their affiliates are expected to vote any common stock ownedemployees may solicit proxies personally and by them in favor of the Extension Amendment Proposal. On the record date, the initial stockholders beneficially ownedtelephone, facsimile, and were entitled to vote 5,750,000 founder shares and 650,000 private shares, representing approximately 21.8% of the Company’s issued and outstanding common stock.
In addition, the Sponsor and the Company’s directors, executive officers and their respective affiliates may choose to buy public shares in the open market and/or through negotiated private purchases. In the event that purchases do occur, the purchasers may seek to purchase shares from stockholders who would otherwise have voted against the Extension Amendment Proposal and elected to convert their shares into a portion of the trust account. Any public shares purchased by affiliatesother electronic means. They will be voted in favor of the Extension Amendment Proposal and the Adjournment Proposal.

23


The affirmative vote of the majority of the Company’s issued and outstanding shares of the Company’s common stock represented in person or by proxy at the special meeting and entitled to vote thereon, is required to approve the Adjournment Proposal. Abstentions and broker non-votes will not have any effect on this proposal.
Interests of the Company’s Directors and Officers
When you consider the recommendation of the Company’s board of directors, you should keep in mind that the Company’s executive officers and members of the Company’s board of directors have interests that may be different from, orreceive no compensation in addition to your interests as a stockholder. These interests include, amongtheir regular salaries. We may request banks, brokers, and other things:

If the Extension Amendment Proposal is not approvedcustodians, nominees, and we do not consummate an initial business combination by February 18, 2022, the 5,750,000 founder shares (including the February 6, 2020, stock dividend of 0.15 share for each founder share outstanding) which were acquired for an aggregate purchase price of $25,000 will be worthless (as the holders have waived liquidation rights with respectfiduciaries to such shares), as will the 650,000 private placement units that were acquired simultaneously with the IPO for an aggregate purchase price of $6,500,000. Such common stock and units had an aggregate market value of approximately $63,932,500 based on the last sale price of $9.96 and $10.25forward copies of the common stockproxy material to their principals and units, respectively, on Nasdaq on December 31, 2021;
to request authority for the execution of proxies. We may reimburse these persons for their expenses in so doing.


In connection with the IPO, the Sponsor has agreed that if the Extension Amendment Proposal is not approved, the Company does not consummate an initial business combination by February 18, 2022 and the Company liquidates, it will be liable under certain circumstances to ensure that the proceeds in the trust account are not reduced by certain claims of target businesses or vendors or other entities that are owed money by the Company for services rendered, contracted for or products sold to the Company;

All rights specified in the Company’s charter relating to the right of officers and directors to be indemnified by the Company, and of the Company’s officers and directors to be exculpated from monetary liability with respect to prior acts or omissions, will continue after an initial business combination. If the Extension Amendment Proposal is not approved, the Company does not consummate an initial business combination by February 18, 2022 and the Company liquidates, the Company will not be able to perform its obligations to its officers and directors under those provisions;

If the Company is unable to complete an initial business combination within the required time period, it will pay the costs of any subsequent liquidation from its remaining assets outside of the trust account. If such funds are insufficient, the Sponsor has agreed to pay the funds necessary to complete such liquidation (currently anticipated to be no more than approximately $15,000) and has agreed not to seek repayment for such expenses.

The Company’s officers, directors and their affiliates are entitled to reimbursement of out-of-pocket expenses incurred by them in connection with certain activities on the Company’s behalf, such as identifying and investigating possible business targets and business combinations. If the Extension Amendment Proposal is not approved and an initial business combination is not consummated by February 18, 2022, these out-of-pocket expenses will not be repaid.
Additionally, if the Extension Amendment Proposal is approved and the Company consummates an initial business combination, the officers and directors may have additional interests that would be described in the proxy statement for such transaction.
Board Recommendation
THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT YOU VOTE “FOR” THE EXTENSION AMENDMENT PROPOSAL AND THE ADJOURNMENT PROPOSAL. THE BOARD OF DIRECTORS EXPRESSES NO OPINION AS TO WHETHER YOU SHOULD CONVERT YOUR PUBLIC SHARES.

24


BENEFICIAL

OWNERSHIP OF SECURITIES

The following table sets forth certain information known by us regarding the beneficial ownership of the Company’s common stockCommon Stock as of the record dateSeptember 5, 2023, by:


each person who is known by us to be the beneficial owner of more than 5% of ourthe outstanding shares of Class A Common Stock and Class B Common Stock;

each of our executive officerscurrent Named Executive Officers and directors that beneficially own sharesdirectors; and
all of our Class A Common Stock and Class B Common Stock; and

allcurrent executive officers and directors as a group.
As

Beneficial ownership is determined according to the rules of the record date, there wereSEC, which generally provide that a totalperson has beneficial ownership of 23,650,000a security if he, she or it possesses sole or shared voting or investment power over that security, including options and warrants that are currently exercisable or exercisable within 60 days.

Unless otherwise noted, all information with respect to beneficial ownership has been furnished by the respective five percent or more stockholders, directors or named executive officers, as the case may be. The beneficial ownership percentages set forth in the table below are based on the Common Stock issued and outstanding as of September 5, 2023. Unless otherwise noted, all persons listed below can be reached at MSP Recovery, Inc., 2701 South Le Jeune Road, Floor 10, Coral Gables, Florida 33134.

Beneficial Stock Ownership Table

 

Class A Common Stock (1)

Class V Common Stock (2)

Beneficial Owner Name

Number of Shares

%

Number of Shares

%

Named Executive Officers & Directors

 

 

 

 

John H. Ruiz (3)(4)

2,085,176,055

94.11%

2,084,157,566

67.09%

Frank C. Quesada (5)(6)

901,928,778

87.35%

901,390,330

29.02%

Ricardo Rivera (7)

46,691

*

-

 

Alexandra Plasencia (8)

35,825

*

-

 

Michael F. Arrigo

6,355

*

-

 

Beatriz Assapimonwait

-

-

-

 

Roger Meltzer (9)(10)(11)

1,190,000

0.90%

-

 

Thomas W. Hawkins (9)(12)(13)

2,420,000

1.82%

-

 

Ophir Sternberg (14)

601,617,492

82.71%

-

 

All directors and officers as a group (9 individuals)

3,592,421,196

98.31%

2,985,547,896

95.75%

 

 

 

 

 

5% Stockholders

 

 

 

 

Virage Recovery Master LP (15)

96,552,851

42.47%

 

 

Oliver SPV Holdings LLC (9)(16)

59,540,075

31.38%

 

 

Alex Ruiz (17)

42,000,000

31.12%

 

 

Paul Rapisarda

21,911,856

14.37%

 

 

JLS Equities LLC (18)

11,912,499

8.36%

 

 

Jessica Wasserstrom (9)(19)

9,527,499

6.73%

 

 

Leviathan Group LLC

8,330,000

5.94%

 

 

John H. Ruiz, II (20)

7,420,004

5.37%

7,420,004

*

Virage Recovery Participation LP (21)

17,095,368

11.56%

17,095,368

*

Series MRCS (22)

413,478,000

75.97%

413,478,000

13.11%

Brickell Key Investments LP (23)

66,666,666

47.01%

 

 

Cano Health

200,000,001

60.38%

 

 


* Less than one percent (1%)

1.
Includes shares of Class A Common Stockcommon stock issuable pursuant to derivatives (including Up-C Units and 5,750,000 shares of Class B Common Stock outstanding. Unless otherwise indicated, we believe all persons named in the table have sole voting and investment power with respect to all shares of Class A Common Stock and Class B Common Stock beneficially owned by them. The following table does not reflect beneficial ownership of the Company’s warrants, as they are notwarrants) exercisable within 60 days of the date of this proxy statement.
Name and Address of Beneficial Owner(1)
Number of
Shares
Beneficially
Owned
Percentage
Shares of
Shares of
Outstanding
Common
Stock
Lionheart Equities, LLC(2)
4,922,50016.74%
Ophir Sternberg(2)
4,922,50016.74%
James Anderson
Paul Rapisarda(3)
40,000*
Tom Byrne
Tom Hawkins
Roger Meltzer
All directors and executive officers as a group (six individuals)5,702,50019.40%
September 5, 2023.
*2.
Includes shares of Class V common stock, which are non-economic voting shares of the Company.
Less than one percent.
(1)3.
This table is based on 23,650,000Includes 172,489 shares of Class A Common Stockcommon stock and 5,750,000846,000 warrants directly held by Mr. Ruiz. In addition to securities directly held by Mr. Ruiz in his individual capacity, includes shares held by the following entities Jocral Family LLLP, Ruiz Group Holdings Limited, LLC and Series MRCS, a series of MDA, Series LLC, a Delaware series limited liability company (“Series MRCS”), including shares held by Series MRCS for the benefit of Jocral Holdings LLC. Reported figures do not include securities held by John Ruiz II, Mr. Ruiz’s son, in his capacity as a Member, or by Alex Ruiz, Mr. Ruiz’s son, of which Mr. Ruiz disclaims beneficial ownership.
4.
Reported figures do not include any attributed ownership based on Mr. Ruiz’s investment in VRM, which have been transferred to affiliated trusts of Mr. Ruiz and of which Mr. Ruiz disclaims beneficial ownership. Messrs. Ruiz and Quesada together invested in VRM, which investment represented a 1.14% ownership interest in VRM. Mr. Ruiz is entitled to 70% of such investment, and Mr. Quesada is entitled to 30% of such investment. As a result, the indirect beneficial ownership attributable to such affiliated trusts would be 0.8% of VRM.
5.
Includes 138,909 shares of Class B Common Stock outstanding asA common stock and 399,539 warrants directly held by Mr. Quesada. In addition to securities directly held by Mr. Quesada in his individual capacity, includes shares held by Quesada Group Holdings LLC and Series MRCS.
6.
Reported figures do not include any attributed ownership based on Mr. Quesada’s investment in VRM, which have been transferred to affiliated trusts of Mr. Quesada and of which Mr. Quesada disclaims beneficial ownership. Messrs. Ruiz and Quesada together invested in VRM, which investment represented a 1.14% ownership interest in VRM. Mr. Ruiz is entitled to 70% of such investment, and Mr. Quesada is entitled to 30% of such investment. As a result, the record date. Beneficialindirect beneficial ownership is determined in accordance with the rules of the SEC. Except as described in the footnotes below and subject to applicable community property laws and similar laws, we believe that each person listed above has sole voting and investment power with respectattributable to such shares. Unless otherwise indicated,affiliated trusts would be 0.3% of VRM.
7.
Includes 46,691 shares of Class A common stock.
8.
Consists of 35,825 shares of Class A common stock held by the spouse of Alexandra Plasencia.
9.
The business address offor each of the entities, directors and executives in this tablethese individuals is c/o, Lionheart Equities LLC, 4218 NE 2nd Avenue, Miami FL 33137.
(2)10.
Based solely upon information contained inRoger Meltzer has been a Schedule 13G filed on February 16, 2021, represents (i) 4,662,500 sharesmember of Class B Common Stock and (ii) 260,000 shares of Class A Common Stock owned directly by Lionheart Equities, LLC, who shares voting and dispositive power over such shares with Mr. Sternberg.the Board since 2021.
(3)11.
Represents (i)Beneficial ownership includes 10,000 shares of Class A Common Stockcommon stock and (ii) 30,0001,180,000 shares of Class B Common Stock owned directly by Mr. Rapisarda.A common stock underlying New Warrants.
12.
The holdersThomas Hawkins has been a member of the founderBoard since 2021. Beneficial ownership includes (i) 50,000 shares have agreed (A) to vote anyof Class A common stock and 2,360,000 shares of Class A common stock underlying New Warrants held in an individual capacity and (ii) 10,000 shares of Class A common stock and 1,180,000 shares of Class A common stock underlying New Warrants held by the Estate of Steven R. Berrard. Thomas Hawkins holds sole voting and investment control over the shares held by the Estate of Steven R. Berrard as the personal representative.
13.
Beneficial ownership includes 50,000 shares of Class A common stock and 2,360,000 shares of Class A common stock underlying New Warrants.
14.
Beneficial ownership includes 114,945,825 shares of Class A common stock issuable upon exchange of the Up-C Units.
15.
Includes (i) 832,498 shares of Class A common stock and 87,320,000 shares of Class A common stock underlying New Warrants owned by Lionheart Investments, LLC; (ii) 1,000,000 shares of Class A common stock and 118,000,000 shares of Class A common stock underlying New Warrants owned by Star Mountain Equities, LLC; (iii) 2,435,060 shares of Class A common stock and 273,029,937 shares of Class A common stock underlying New Warrants owned by Sponsor; and (iv) 1,000,000 shares of Class A common stock and 118,000,000 shares of Class A common stock underlying New Warrants owned by the 2022 OS Irrevocable Trust. Mr. Sternberg holds sole voting and investment control over the shares held by each of Lionheart Investments, LLC, Star Mountain Equities, LLC, and Sponsor as the sole manager. Mr. Sternberg’s spouse holds sole voting and investment control over the shares owned by themthe 2022 OS Irrevocable Trust as its trustee and as a result, Mr. Sternberg may be deemed to have beneficial ownership of the shares owned by the 2022 OS Irrevocable Trust.
16.
Beneficial ownership includes 58,990,077 shares of Class A common stock underlying New Warrants. Alan Rubenstein holds sole voting and investment control over the shares held by Oliver SPV Holdings, LLC as its manager. The address for Mr. Rubenstein and Oliver SPV Holdings, LLC is 822 Oliver St, Woodmere, NY 11598.
17.
Alex Ruiz is the son of John H. Ruiz, the Company’s Chief Executive Officer.


18.
Beneficial ownership includes 112,499 shares of Class A common stock and 11,800,000 shares of Class A common stock underlying New Warrants. Jacob Sod holds sole voting and investment control over the shares held by JLS Equities LLC as its manager. The address for Jacob Sod and JLS Equities LLC is 58 Larch Hill Rd, Lawrence, NY 11559.
19.
Beneficial ownership includes 87,499 shares of Class A common stock and 9,440,000 shares of Class A common stock underlying New Warrants.
20.
John H. Ruiz, II is the son of John H. Ruiz, the Company’s Chief Executive Officer. Beneficial ownership includes 7,420,004 shares of Class A common stock issuable upon exchange of the Up-C Units held in favoran individual capacity.
21.
Beneficial ownership includes 5,065,769 shares of Class A common stock issuable upon exchange of the Up-C Units.
22.
Includes 124,043,400 Up-C Units held by Series MRCS that are beneficially owned by Frank C. Quesada and 289,434,600 shares beneficially owned by John H. Ruiz (including through his affiliate, Jocral Holdings, LLC).
23.
Includes 66,666,666 shares of Class A common stock issuable upon exercise of the CPIA Warrant pursuant to the Amendment and the Warrant Agreement with the Holder.


MATTERS TO COME BEFORE THE ANNUAL MEETING

PROPOSAL 1

ELECTION OF DIRECTORS

Our Board of Directors currently consists of seven directors divided into three classes: Class I, Class II and Class III. There are currently two Class I directors, two Class II directors, and three Class III directors, with one class being elected each year to serve a staggered three-year term.

Class I directors shall serve for a term expiring at the 2023 Annual Meeting of Stockholders;
Class II directors shall serve for a term expiring at the 2024 Annual Meeting of Stockholders; and
Class III directors shall serve for a term expiring at the 2025 Annual Meeting of Stockholders.

At this Annual Meeting and each Annual Meeting thereafter, the successors to the class of directors whose terms expire at that meeting would be elected for a term of office to expire at the third succeeding Annual Meeting after their election, or until their successors have been duly elected and qualified.

Our Class I directors are Roger Meltzer and Beatriz M. Assapimonwait; our Class II directors are Michael F. Arrigo and Thomas Hawkins; and our Class III directors are John H. Ruiz, Frank C. Quesada, and Ophir Sternberg.

Our Board of Directors is recommending that Roger Meltzer and Beatriz M. Assapimonwait, our Class I directors, be re-elected to serve for a term until the 2026 Annual Meeting or until their successors are duly elected and qualified or until their earlier resignation or removal. If Roger Meltzer or Beatriz M. Assapimonwait become unavailable for any reason, including a situation which is not anticipated, substitute nominees may be proposed by the Board, and any shares represented by proxy will be voted for the substitute nominee, unless the Board reduces the number of directors.

The following table sets forth certain information concerning the nominees for Class I directors and each of the other members of the Board of Directors:


Directors and Executive Officers Summary

Below are the names of and certain information regarding our executive officers and directors:

Directors

Age

Position

John H. Ruiz

56

Class III Director

Frank C. Quesada

43

Class III Director

Ophir Sternberg

53

Class III Director

Beatriz Maria Assapimonwait

61

Class I Director

Michael Arrigo

65

Class II Director

Thomas Hawkins

62

Class II Director

Roger Meltzer

72

Class I Director

Executive Officers

Position

John H. Ruiz

56

Chief Executive Officer

Frank C. Quesada

43

Chief Legal Officer

Ricardo Rivera

52

Chief Operating Officer & Interim Chief Financial Officer

Alexandra Plasencia

38

General Counsel


DIRECTORS

img191178444_8.jpg 

John H. Ruiz

Founder, Chief Executive Officer & Chair of the Board

Director since: 2022

Age: 56

Committees: Nominating & Corporate Governance

Experience:John H. Ruiz is a founder of LifeWallet and has served as Chief Executive Officer since the Company’s inception (in 2014 as MSP Recovery). Mr. Ruiz was named one of Lawyers of Distinction’s “2023 Power Lawyers,” for his accomplishments in healthcare law. He was also named “2019’s DBR Florida Trailblazer,” for his work in integrating data analytics into the practice of law, and for its positive impact on healthcare recoveries across the mainland U.S. and Puerto Rico. Over the course of his 30-year legal career, Mr. Ruiz has gained national recognition in class action, mass tort litigation, MDL consolidated cases, medical malpractice, products liability, personal injury, real estate, and aviation disaster cases. Recently, Mr. Ruiz led the legal strategy in the landmark victory handed down by the U.S. Court of Appeals for the Eleventh Circuit, in MSP Recovery Claims Series v. Ace American (11th Cir.). In addition, he has certified more than 100 class actions and led MSP’s participation in Humana v. Western Heritage (11th Cir.), MSP Recovery v. Allstate (11th Cir.), and MSPA Claims 1, LLC v. Kingsway Amigo Ins. Co. (11th Cir.). Mr. Ruiz has been involved as counsel in cases that have totaled more than $20 billion in settlements. These class actions resulted in some of the largest awards in Florida against major insurance companies. In total, Mr. Ruiz has certified class actions against major car insurers in the State of Florida, resulting in the current and potential redistribution of billions of dollars in improperly paid claims spanning a period of more than 10 years. Starting as early as 1996, Mr. Ruiz filed class-action lawsuits on behalf of more than 30,000 Miami-Dade County residents against the Florida Department of Agriculture for trespassing onto the private properties of homeowners and chopping down their citrus trees without any compensation. The case was ultimately certified, and the Department of Agriculture directly compensated all members of the aggrieved class. In 2001, Mr. Ruiz represented consumers in a class action lawsuit against Firestone that resulted in dozens of fatalities and thousands of serious blowouts. Mr. Ruiz was also hired as local counsel by numerous out of state law firms that had pending cases in Florida courts. The cases in aggregate settled for more than $30 million. Mr. Ruiz also represented the families of crash victims in a wrongful death suit against Chalk’s International Ocean Airway. Mr. Ruiz was the first lawyer to file a limited fund class action. The case settled for a confidential agreed amount. Mr. Ruiz is licensed to practice before the Court of Appeals for the Fourth Circuit, the US Court of Appeals for the Second Circuit, the US Court of Appeals for the Third Circuit, and the Florida Supreme Court.

Skills & Expertise: Mr. Ruiz brings to the Board leadership, legal, strategic, operational, brand management, and data analytics expertisefrom his expansive legal career, business background, and use of technology in his law practice. He has experience formulating legal strategy and case development from his work leading La Ley con John H. Ruiz. Mr. Ruiz has vast leadership and business strategy experience having founded or led companies across a variety of sectors, including legal, media, aviation, and manufacturing companies. Mr. Ruiz designed and developed information systems that streamlined his law practice and algorithms that analyze terabytes of data to identify and pursue recoveries in a variety of lawsuits. Mr. Ruiz’s mastery of brand development is evidenced by his pioneering of panel format television and radio to reach audiences, and his recent development of LifeWallet Sports to raise brand awareness through college athlete spokespersons.


img191178444_9.jpg 

Frank C. Quesada

Founder & Chief Legal Officer

Director since: 2022

Age: 43

Committees: Nominating & Corporate Governance

Experience: Frank C. Quesada is a founding member of LifeWallet and has served as Chief Legal Officer since its inception. Mr. Quesada is also a Partner at MSP Recovery Law Firm. With over 16 years of healthcare and complex commercial litigation experience, Mr. Quesada oversees LifeWallet’s in-house attorneys and several nationally recognized law firms that assist MSP Recovery Law Firm in their recovery efforts. Additionally, he develops LifeWallet’s legal strategies and spearheads execution. Notably, Mr. Quesada led the execution of federal appellate strategies in MSP Recovery cases resulting in landmark legal victories and new Medicare Secondary Payer Act precedent benefitting Medicare entities across the country. These legal victories include MSP Recovery v. Allstate (11th Cir.), MSPA Claims 1 v. Tenet (11th Cir.), MSPA Claims 1 v. Kingsway Amigo (11th Cir.), and MSP Recovery Claims Series v. Ace American (11th Cir.). Mr. Quesada currently serves on the Board of Directors of USA Water Polo, Inc.

Skills & Expertise: Mr. Quesada brings to the Board leadership, legal, strategic, operational, governmental, business development, and data analytics expertise.Mr. Quesada brings a depth of legal and strategic experience from years of complex commercial litigation. Having served in elected office, Mr. Quesada leverages years of experience navigating the political landscape, creating and influencing policy. This experience carries over to the business world, making Mr. Quesada an effective communicator and advocate on behalf of the Company with bankers and potential clients. Prior to the Company and MSP Recovery Law Firm, Mr. Quesada managed his own law firm, overseeing attorneys with a substantial case load in the hospitality industry.


img191178444_10.jpg 

Ophir Sternberg

Board Member

Director since: 2022

Age: 53

Experience: Ophir Sternberg is a Board Member of the Company, and was previously the Chairman, President and Chief Executive Officer of Lionheart Acquisition Corporation II, the SPAC through which MSPR became a publicly traded company. Mr. Sternberg is the Founder and Chief Executive Officer of Miami/Fort Lauderdale based Lionheart Capital, founded in 2010. Mr. Sternberg began his career assembling, acquiring, and developing properties in emerging neighborhoods in New York City, which established his reputation for identifying assets with unrealized potential and combining innovative partnerships with efficient financing structures to realize above average returns. Mr. Sternberg came to the United States in 1993 after completing three years of military service within an elite combat unit for the Israeli Defense Forces. In March 2020, Mr. Sternberg became Chairman of Nasdaq-listed OPES, and on June 30, 2020, announced the SPAC’s initial business combination with BurgerFi, a fast-casual “better burger” concept that consists of approximately 120 restaurants nationally and (B)internationally. The OPES-BurgerFi business combination closed on December 16, 2020 and Mr. Sternberg is the Executive Chairman of the post-combination Nasdaq-listed company, BurgerFi International, Inc. (NASDAQ: BFI). On October 11, 2021, BurgerFi, led by Ophir Sternberg as Executive Chairman, announced the acquisition of Anthony’s Coal Fired Pizza & Wings, creating a multi-brand platform of premium casual restaurant concepts. With the acquisition of Anthony’s, BurgerFi now has 180 systemwide restaurant locations across the country through its two premium casual dining brands, with 61 Anthony’s locations and 119 BurgerFi locations. Mr. Sternberg is also the Chairman, President, and Chief Executive Officer of Lionheart III Corp, a SPAC that was originally formed for a $100 million raise, but on November 8, 2021, closed on its initial public offering at an upsized $125 million. Lionheart III Corp, under the ticker symbol LION, was welcomed into the Nasdaq family. On July 26, 2022, Lionheart III announced its business combination agreement with Security Matters Limited (“SMX”) (ASX:SMX), a publicly traded company on the Australian Securities Exchange, bringing the expected combined entity value to $360M. SMX creates a sustainable system within the current supply chain, designed for the 21st century economy. The SMX business combination closed on March 8, 2023.

Skills & Expertise: Mr. Sternberg brings to the Board leadership, strategic, operational, finance and business structuring, and capital markets experience.Mr. Sternberg is qualified to serve as a director due to his extensive experience in both the public and private company sectors. Having successfully launched a number of public companies, Mr. Sternberg is intimately familiar with the capital markets and large scale financing. Mr. Sternberg serves on the board of several public companies, and has led successful corporate growth strategies. Mr. Sternberg’s leadership qualities are demonstrated in his leadership positions over a variety of business sectors, including healthcare, hospitality, and technology.


img191178444_11.jpg 

Beatriz M. Assapimonwait

Board Member

Director since: 2022

Age: 61

Committees: Compensation

Experience:Beatriz (Betty) Assapimonwait has over 40 years of experience in the managed health care industry. Ms. Assapimonwait was, up until August 2021, Regional President for the South Florida region at Humana Inc. (NYSE:HUM) ("Humana"), one of the largest private insurance health insurers in the U.S. with a focus on administering Medicare Advantage plans. In her role at Humana, Ms. Assapimonwait was responsible for developing market strategies and leading all market operations for all Medicare lines of business, including HMOs and PPOs for the South Florida region. Prior to her role at Humana, she served as CEO of Family Physicians of Winter Park, Inc., until its acquisition by Humana, where from December 2016 to July 2019, she led the strategic and operational efforts of a global risk MSO with 22 primary clinics in the Central Florida Region. Additionally, she served as the Vice President of Medicare Advantage Prescription Drug Plans at Aetna, Inc. from November 2014 to November 2016; Chief Operations Officer at Innovacare Health, from January 2014 to October 2014; Founder and President of Seven Stars Quality Healthcare, from July 2013 to December 2013; and Regional President for the North Florida region at Humana, from January 2009 to June 2013. Ms. Assapimonwait was appointed to serve on the board of directors of CareMax Inc. (Nasdaq:CMAX) in September 2021 and also serves as the Chair of the Strategy and Operations Committee since September 2021. She earned her Bachelor of Arts degree from Florida International University in 1983, and is certified in Healthcare Compliance by the Health Care Compliance Association and in HIPAA Compliance from Kennesaw State University. She has won several awards and commendations, including being a Stevie Award Finalist of the American Business Awards for Best Customer Service Organization in 2004 and appointed Preceptor and Clinical Adjunct Faculty for the Healthcare Administration Program in 1997 at the University of Houston-Clear Lake.

Skills & Expertise: Ms. Assapimonwait brings to the Board leadership, strategic, operational, and healthcare industry experience.A proven effective leader, Ms. Assapimonwait has served in director and officer positions for large-scale healthcare companies, leading strategy and operations initiatives. Ms. Assapimonwait has relevant experience in the pharmaceutical industry and with Medicare Advantage drug plans.


img191178444_12.jpg 

Michael F. Arrigo

Board Member

Director since: 2022

Age: 65

Committees: Audit, Compensation

Experience: Michael F. Arrigo is a co-founder and the chief executive officer of No World Borders, Inc., a healthcare data, regulations, and economics firm with clients in the pharmaceutical, medical device, hospital, surgical center, physician group, diagnostic imaging, laboratory and genetic testing, health information technology, and health insurance markets. In his role at No World Borders, Inc., Mr. Arrigo advises MAOs who provide health insurance under Part C of the Medicare Act and serves as an expert witness regarding medical coding and medical billing, fraud damages, HIPAA privacy, and Electronic Health Record software. Prior to his current role, Mr. Arrigo served as Vice President at First American Financial (NYSE: FAF) from October 2002 to February 2007, overseeing eCommerce and regulatory compliance technology initiatives for top mortgage banks; Vice President of Fidelity National Financial (NYSE: FNF) from 2002 to 2003; chief executive officer of one of the first cloud-based billing software companies, Erogo, from 2000 to 2002; Vice President of Marketing for an email encryption and security software company until its acquisition by a company that merged into Axway Software SA (Euronext: AXW.PA) from 1999 to 2000; CEO of LeadersOnline, an online recruiting venture of Heidrick & Struggles from 1997 to 1999; management consultant to Hewlett Packard, Oracle, and Symantec from 1994 to 1997; Vice President of Marketing for a software company acquired by a company that merged into Cincom Systems from 1992 to 1994; Product Manager at Ashton-Tate from 1987 to 1992 responsible for database software products including Microsoft/Sybase SQL Server. Mr. Arrigo earned his Bachelor of Science in Business Administration from the University of Southern California in 1981. His post-graduate studies include biomedical ethics at Harvard Medical School, biomedical informatics at Stanford Medical School, blockchain and crypto-economics at the Massachusetts Institute of Technology, and training as a Certified Professional Medical Auditor (CPMA).

Skills & Expertise: Mr. Arrigo brings to the Board leadership, strategic, regulatory, information technology, finance, and Medicare Advantage industry experience.Mr. Arrigo has broad business experience. A data specialist, Mr. Arrigo is intimately familiar with data management and analysis and across the healthcare industry spectrum. He is admitted as an expert in court in healthcare privacy and cybersecurity (commonly known as HIPAA and the companion regulations such as the ARRA HITECH Act) and led the Sarbanes Oxley internal audit for a public Fortune 100 firm in compliance with the Public Company Accounting Oversight Board (PCAOB) Standards. He qualifies as a financial expert as defined in Item 407(d)(5) of Regulation S-K promulgated under the Securities Act of 1933, as amended (the “Securities Act”). Mr. Arrigo has also been admitted by courts as an expert in fair market value physician compensation and corporate governance. Having served in senior leadership positions at a variety of information technology and finance companies, Mr. Arrigo is a proven valuable advisor and strategist.


img191178444_13.jpg 

Thomas Hawkins

Board Member

Director since: 2022

Age: 62

Committees: Audit

Experience:Since March 2023, Thomas Hawkins has served on the board of directors of SMX (Security Matters) Public Limited Company, a technology company that enables materials to carry a history that can be authenticated through organization, use, recycle, and multiple reuse cycles; he is also a member of the company's Risk and Audit Committee. Mr. Hawkins previously served as a Management Consultant for MEDNAX, Inc. from February 2014 to December 2017, after serving as General Counsel and Board Secretary from April 2003 to August 2012. Prior to that, Mr. Hawkins worked for New River Capital Partners as a Partner from January 2000 to March 2003; AutoNation, Inc. as Senior Vice President of Corporate Development from May 1996 to December 1999; Viacom, Inc. as Executive Vice President from September 1994 to May 1996; and Blockbuster Entertainment Corporation as Senior Vice President, General Counsel, and Secretary from October 1989 to September 1994. Mr. Hawkins currently serves on the board of directors of the Alumni Association of the University of Michigan, holding the position of Treasurer and thus leading the Finance Committee of the board. Mr. Hawkins also serves on the board of directors of Jumptuit Inc., a data analytics technology company. Mr. Hawkins received his Juris Doctor from Northwestern University in 1986 and his A.B. in Political Science from the University of Michigan in 1983.

Skills & Expertise: Mr. Hawkins brings to the Board leadership, finance, business, legal, and finance experience.Mr. Hawkins led companies across a variety of industries, including finance, entertainment, information technology, and retail sales. An experienced advisor, Mr. Hawkins is qualified to serve as a director due to his experience as a senior executive and chief legal officer at several public companies (including his experience acquiring companies and in finance) and with counseling and serving on boards of directors.


img191178444_14.jpg 

Roger Meltzer

Board Member

Director since: 2022

Age: 72

Committees: Audit

Experience: Mr. Meltzer practiced law at DLA Piper LLP from 2007 and held various roles: Global Co-Chairman (2015 through 2020), and currently as Chairman Emeritus; Americas Co-Chairman (2013 through 2020); Member, Office of the Chair (2011 through 2020); Member, Global Board (2008 through 2020); Co-Chairman, U.S. Executive Committee (2013 through 2020); Member, U.S. Executive Committee (2007 through 2020); and Global Co-Chairman, Corporate Finance Practice (2007 through 2015). Prior to joining DLA Piper LLP, Mr. Meltzer practiced law at Cahill Gordon & Reindel LLP from 1977 to 2007 where he was a member of the Executive Committee from 1987 through 2007, Co-Administrative Partner and Hiring Partner from 1987 through 1999, and Partner from 1984 through 2007. Mr. Meltzer currently serves on the Advisory Board of Harvard Law School Center on the Legal Profession (May 2015—Present); and the Board of Trustees, New York University Law School (September 2011—Present); and previously served on the Corporate Advisory Board, John Hopkins, Carey Business School (January 2009—December 2012). He has previously served on the board of directors of: Lionheart II Corp (March 2021 to May 2022), Lionheart III Corp (March 2021 to August 2022), Haymaker Acquisition Corp. III (February 2021 to July 2022), certain subsidiaries of Nordic Aviation Capital (December 2021 to April 2022), The Legal Aid Society (November 2013 to January 2020), Hain Celestial Group, Inc. (December 2000 to February 2020), American Lawyer Media (January 2010 to July 2014) and The Coinmach Service Corporation (December 2009 to June 2013). Mr. Meltzer has also received several awards and honors and has been actively involved in philanthropic activity throughout his career. Mr. Meltzer received his Juris Doctor degree in law from New York University School of Law and an A.B. from Harvard College. In February 2021, Mr. Meltzer joined the board of directors of Haymaker Acquisition Corp. 4, a special purpose acquisition company focused on identifying and implementing value creation initiatives within the consumer and consumer-related products and services industries. In February 2021, Mr. Meltzer joined the board of directors of Ubicquia LLC, a smart solutions infrastructure company. In May 2022, Mr. Meltzer joined the board of directors of MSP Recovery, Inc. following its business combination with Lionheart Acquisition Corp. II. In June 2022, Mr. Meltzer joined the board of directors of Aearo Holding LLC and affiliated entities. In August 2022, Mr. Meltzer joined the board of directors of Empatan Public Limited Company (“SMX”) following its business combination with Lionheart III Corp, Security Matters Limited and Aryeh Merger Sub Inc. In January 2023, Mr. Meltzer joined the board of directors of AID Holdings II (“Enlivant”), a senior living facility provider and portfolio company of TPG Capital L.P. In February 2023, Mr. Meltzer joined the board of directors of Klein Hersh, an executive recruitment firm that spans the life sciences continuum and healthcare industry. In April 2023, Mr. Meltzer joined the board of directors of Cyxtera Technologies, Inc., a company specializing in colocation and interconnection services, with a footprint of more than 60 data centers in over 30 markets. In May


2023, Mr. Meltzer joined the board of directors of John C. Heath, Attorney at Law PC d/b/a/ Lexington Law, an industry leader specializing in credit repair services.

Skills & Expertise: Mr. Meltzer brings to the Board legal, finance, business, legal, and leadership experience.Mr. Meltzer is qualified to serve as a director due to his experience representing clients on high-profile, complex, and cross-border matters and his leadership qualities in managing a large international organization. During his tenure, DLA Piper was subject to a large-scale cybersecurity infiltration, and Mr. Meltzer was a leader of a small group of senior executives that managed the firm through that cyberattack.


Board Diversity Matrix (as of June 30, 2023)

 

Male

Female

Non-Binary

Did Not Disclose Gender

Part I: Gender Identity

 

 

 

 

Directors

6

1

 

 

Part II: Demographic Background

 

 

 

 

African American or Black

 

 

 

 

Alaskan Native or American Indian

 

 

 

 

Asian

 

 

 

 

Hispanic, Latino or Latina

3

 

 

 

Native Hawaiian or Pacific Islander

 

 

 

 

White

4

 

 

 

Two or More Races or Ethnicities

 

 

 

 

LGBTQ+

1

 

 

Undisclosed

 

 

 

 

Vote Required and Board Recommendation

The vote required to elect our two Class I directors named in this proxy statement, each for a three-year term expiring at the 2026 Annual Meeting or until their successors are duly elected and qualified, is a plurality of the votes of the shares of Common Stock cast at the Annual Meeting. The Board recommends that you vote “FOR” the re-election of each of the Class I director nominees named in this proxy statement.


MATTERS TO COME BEFORE THE ANNUAL MEETING

PROPOSAL 2

RATIFICATION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

The Audit Committee has selected Deloitte as LifeWallet’s independent registered public accounting firm to audit the consolidated financial statements of LifeWallet for the fiscal year ending December 31, 2023, which will include an audit of the effectiveness of LifeWallet’s internal control over financial reporting.

A representative of Deloitte is expected to be present at the meeting. The representative will have the opportunity to make a statement if he or she desires to do so and is expected to be available to respond to appropriate questions.

Stockholder ratification of the selection of our independent registered public accounting firm is a matter of good corporate practice. In the event that this selection is not ratified by the affirmative vote of a majority of the shares cast during the meeting or by proxy of stockholders entitled to redeemvote at the meeting, the appointment of the independent registered public accounting firm may be reconsidered by the Audit Committee. Even if the selection is ratified, the Audit Committee in its discretion may direct the appointment of a different accounting firm at any sharestime during the year if the Audit Committee determines that such a change would be in the best interests of LifeWallet and our stockholders.

Principal Accounting Fees and Services

The following is a summary of the fees billed to us by Deloitte for professional services rendered for the fiscal year ending December 31, 2022.

Accounting Fees and Services

Fee Category

2021

2022

Audit Fees

$557,795

$1,019,744

Audit-Related Fees

$895,821

Tax Fees

All Other Fees

Total Fees

$557,795

$1,915,565


Audit Fees. The aggregate audit fees (inclusive of out-of-pocket expenses) billed by Deloitte were for professional services rendered for the audit of our annual financial statements and review of financial statements included in our Annual Report on Form 10-K filed with the SEC, and for services that are normally provided by the independent registered certified public accountants in connection with a stockholder vote to approve a proposed business combination. If wesuch filings, including amendments, or engagements for the fiscal year ended December 31.

Audit Related Fees. This category consists of assurance and related services by the independent registered public accounting firm that are unable to effect an initial business combination and liquidate, there will be no liquidation distribution with respectreasonably related to the insider shares.


25


STOCKHOLDER PROPOSALS
Ifperformance of the Extension Amendment Proposal is approvedaudit or review of our financial statements and the Extension is implemented, the Company’s next annual meeting of stockholders will likely be held on or about December 31, 2022, unless the date is changed by the Company’s board of directors. If you are a stockholder and you want to include a proposal in the proxy statementnot reported above under “Audit Fees.” The services for the next annual meeting, you need to provide it to the Company by no later than approximately August 5, 2022. You should direct any proposals to the Company’s secretary at the Company’s principal office. If you are a stockholder and you want to present a matter of business tofees that would normally be considered or nominate a director to be elected at the next annual meeting,disclosed under the Company’s bylaws you must give timely notice of the matter or the nomination, in writing, to the Company’s secretary. To be timely, the notice has to be given between 90 and 120 days before the annual meeting date (or between August 31, 2022 and September 30, 2022, if the next annual meeting is held on December 31, 2022).
If the Extension Amendment Proposal is not approved, there will be no further annual meetings of the Company.

26


DELIVERY OF DOCUMENTS TO STOCKHOLDERS
Pursuant to the rules of the SEC, the Company and its agents that deliver communications to its stockholders are permitted to deliver to two or more stockholders sharing the same address a single copy of the Company’s proxy statement. Upon written or oral request, the Company will deliver a separate copy of the proxy statement to any stockholder at a shared address who wishes to receive separate copies of such documents in the future. Stockholders receiving multiple copies of such documents may likewise request that the Company deliver single copies of such documents in the future. Stockholders may notify the Company of their requests by calling or writing the Company at the Company’s principal executive offices at 4218 NE 2nd Avenue, Miami, Florida 33137.

27


WHERE YOU CAN FIND MORE INFORMATION
The Company files reports, proxy statements and other informationthis category include consultation regarding our correspondence with the SEC and other accounting consulting.

Tax Fees. This category consists of professional services rendered by our independent registered public accounting firm for tax compliance, tax advice and tax planning. The services for the fees that would normally be disclosed under this category include tax return preparation and technical tax advice.

All Other Fees. This consists of fees billed for products and services other than those described above.

Pre-Approval of Audit and Non-Audit Services

The Audit Committee has established a policy to review and approve the engagement of our independent auditors to perform audit services and any permissible non-audit services.

Vote Required and Board Recommendation

The vote required for the ratification of the selection of Deloitte as required byour auditor is the affirmative vote of a majority of the votes cast at the Annual Meeting. The Board recommends that you vote “FOR” the ratification of the selection of Deloitte as our auditor.



SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Proxy Statement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended. Youamended (the “Exchange Act”). Forward-looking statements are all statements (and their underlying assumptions) included in this Proxy Statement that refer, directly or indirectly, to future events or outcomes and, as such, are inherently not factual, but rather reflect only our current projections for the future. Consequently, forward-looking statements usually include words such as “estimate,” “intend,” “plan,” “predict,” “seek,” “may,” “will,” “should,” “would,” “could,” “anticipate,” “expect,” “believe,” or similar words, in each case, intended to refer to future events or circumstances. Our future results may readdiffer materially from our past results and copy reports, proxyfrom those projected in the forward-looking statements due to various uncertainties and other informationrisks, including, but not limited to, those included under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, as filed by the Company with the SEC on July 27, 2023. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof and are based upon information available to us at its publicthis time. These statements are not guarantees of future performance. We disclaim any obligation to update information in any forward-looking statement. Actual results could vary from our forward-looking statements due to the factors described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, as well as other important factors.


CORPORATE GOVERNANCE

Corporate Governance Principles and Code of Ethics

Our Board is committed to sound corporate governance principles and practices. In order to clearly set forth our commitment to conduct our operations in accordance with our high standards of business ethics and applicable laws and regulations, our Board adopted Corporate Governance Guidelines applicable to our directors, executive officers and employees that complies with the rules and regulations of Nasdaq. A copy of our Corporate Governance Guidelines is available on our corporate website at https://investor.lifewallet.com, in the “Documents & Charters” section in the “Corporate Governance” tab. The information on our website shall not be deemed incorporated by reference room located at 100 F Street, N.E., Washington, D.C. 20549-1004.in this Proxy Statement. You also may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. You may also obtain copies of the materials described above at prescribed rates by writing to the SEC, Public Reference Section, 100 F Street, N.E., Washington, D.C. 20549-1004. The Company files its reports, proxy statements and other information electronically with the SEC. You may access information on the Company at the SEC website containing reports, proxy statements and other information at http://www.sec.gov. This proxy statement describes the material elements of relevant contracts, exhibits and other information attached as annexes to this proxy statement. Information and statements contained in this proxy statement are qualified in all respects by reference to thewithout charge a printed copy of the relevant contract or other document included as an annex to this document.

This proxy statement contains importantCorporate Governance Guidelines by sending a written request to: LifeWallet General Counsel, 2701 South Le Jeune Road, Floor 10, Coral Gables, Florida 33134.

Board of Directors

The business and affairs of the Company are managed by or under the direction of the Board. The Board is currently composed of seven members.

The Board held eight meetings and acted by written consent on seven occasions during the year ended December 31, 2022. In 2022, each person serving as a director attended at least 75% of the total number of meetings of our Board and any Board committee on which he or she served.

Board Committees

Pursuant to our bylaws, our Board may establish one or more committees of the Board however designated, and delegate to any such committee the full power of the Board, to the fullest extent permitted by law.

The standing committees of our Board currently include an Audit Committee, a Compensation Committee, and a Nominating and Corporate Governance Committee. Each of the committees reports to the Board as such committee deems appropriate and as the Board may request. The composition, duties, and summary of responsibilities of these committees are as follows:


img191178444_15.jpg 

Audit Committee

Mr. Hawkins, Mr. Meltzer, and Mr. Arrigo serve on the Audit Committee. Mr. Hawkins qualifies as the Audit Committee financial information about us thatexpert as defined in Item 407(d)(5) of Regulation S-K promulgated under the Securities Act of 1933, as amended (the “Securities Act”), and serves as Chairperson of the Audit Committee. The Audit Committee operates under a written charter adopted by the Board of Directors. The charter contains a detailed description of the scope of the Audit Committee’s responsibilities and how they will be carried out. According to its charter, the Audit Committee shall consist of at least three members, each of whom shall be a non-employee director who has been determined by the Board to meet the independence requirements of Nasdaq, and also Rule 10A-3(b)(1) of the SEC, subject to the exemptions provided in Rule 10A-3(c). The Audit Committee’s charter is not included in or delivered with this document. You may obtain this additional information, or additional copies of this proxy statement, at no cost,available on our website at www. lionheartacquisitioncorp.comhttps://investor.lifewallet.com, in the “Documents & Charters” section in the “Corporate Governance” tab. The information on our website shall not be deemed incorporated by reference in this proxy statement. The Audit Committee held two meetings during the year ended December 31, 2022.

The Audit Committee’s charter describes the primary functions of the Audit Committee, including, but not limited to, the following:

A.
Oversight of the Independent Auditor
retention of the independent auditor;
assessment the independent auditor’s independence;
evaluation of the qualifications and youperformance of the independent auditors;


oversight of the work of the independent auditor;
establish the terms of the audit engagement;
consider rotation of the independent auditor; and
consider for approval services proposed by the independent auditor for the Company.
B.
Financial Statements and Other Financial Disclosures
review and discuss with management and the independent auditor critical accounting policies and practices used by the Company and consider significant changes thereto;
review and discuss with management and the independent auditor the audited and unaudited financial statements;
submit an annual audit committee report for inclusion in the proxy statement or annual report; and
review earnings releases with management and the independent auditor.
C.
Controls and Procedures
oversee management’s design and maintenance of the Company’s internal control over financial reporting, disclosure controls, and procedures;
review and discuss with management and the independent auditor the certifications and related disclosures by the CEO and CFO in periodic reports; and
maintain policies regarding the hiring of employees and former employees of the independent auditor.
D.
Risk Management, Compliance, and Ethics
review and discuss with management and the independent auditor significant risks or exposures, including cybersecurity, privacy standards, and the Company’s policies and processes with respect to risk assessment and risk management;
review legal, regulatory, and compliance matters, the Company’s Code of Business Conduct and Ethics for changes deemed necessary, and requested waivers;
establish “whistleblower” procedures; and
review related person transactions and other significant conflicts of interest.
E.
Self-Evaluation, Reporting, and Other
conduct period self-evaluations of the Audit Committee performance;


report regularly to the Board of Directors; and
undertake such other responsibilities delegated to the Audit Committee from time to time.

Compensation Committee

Mr. Arrigo and Ms. Assapimonwait serve on the Compensation Committee. Mr. Arrigo serves as the Chairperson of the Compensation Committee. The Compensation Committee operates under a written charter adopted by the Board of Directors. The charter contains a detailed description of the scope of the Compensation Committee’s responsibilities and how they will be carried out. The Compensation Committee’s charter is available on our website at https://investor.lifewallet.com, in the “Documents & Charters” section in the “Corporate Governance” tab. The information on our website shall not be deemed incorporated by reference in this proxy statement. The Compensation Committee may askdelegate any questions youof its responsibilities to one or more subcommittees as the Compensation Committee may from time to time deem appropriate. The Compensation Committee held two meetings during the year ended December 31, 2022.

The Compensation Committee’s duties, which are specified in our Compensation Committee’s charter, include, but are not limited to:

A.
Compensation Oversight
establish and oversee compensation philosophy and programs;
review and approve corporate goals and objectives relevant to officer compensation;
evaluate the CEO and other executive officers’ performance against corporate goals and objectives;
review and approve employment, compensation, benefit, and severance agreements;
review management compensation programs and recommend modifications;
approve special perquisites and other compensation and benefit arrangements;
review, approve, recommend, and administer equity-based compensation plans;
review and approve non-equity based compensation plans;
after the Company ceases to be an “emerging growth company,” (i) review compensation to assess whether policies and practices could lead to excessive risk taking behavior, (ii) conduct a say-on-pay vote and recommend the frequency of say-on-pay votes, and (iii) produce a report on executive compensation if required, review and discuss with management the “Compensation Discussion and Analysis” required by the SEC;
assess engagement agreements with, and the work of, compensation consultants;
if the Company ceases to be a “controlled company” assess the independence of compensation consultants and other advisors to the committee;


recommend to the Board for approval general principles for determining director compensation; periodically review executive officer stock ownership; and
review and oversee stockholder proposals relating to compensation matters.
B.
Self-Evaluation, Reporting, and Other
conduct period self-evaluations of the Compensation Committee performance;
report regularly to the Board of Directors; and
undertake such other responsibilities delegated to the Compensation Committee from time to time.

The charter provides that the Compensation Committee is empowered to inquire into any matter that it considers appropriate to carry out its responsibilities, with access to all books, records, facilities and personnel of the Company, and, subject to the direction of the Board, the Committee is authorized and delegated the authority to act on behalf of the Board with respect to any matter it determines to be necessary or appropriate to the accomplishment of its purposes.

The Compensation Committee may, in its sole discretion, retain or obtain the advice of a compensation consultant, legal counsel or other adviser and will be directly responsible for the appointment, compensation and oversight of the work of any such adviser.

So long as the Company remains a “controlled company” under the rules applicable to companies listed on the Nasdaq Stock Market, each member of the Committee shall not be required to be an “independent” director in accordance with the applicable listing standards of Nasdaq, including for the purposes of serving on the Compensation Committee. If the Company ceases to be a “controlled company,” the Committee shall assess the independence of compensation consultants, legal, and other advisers to the Committee, taking into consideration the factors specified in the listing standards of Nasdaq prior to the retention of any advisers to the Committee, and annually or from time to time as the Committee deems appropriate.

The Committee shall recommend to the Board for approval general principles for determining the form and amount of director compensation, and, subject to such principles, shall evaluate annually the status of Board compensation in relation to comparable U.S. companies (in terms of size, business sector, etc.), reporting its findings and recommendations to the Board for approval.

Compensation Consultant

In December 2022, the Company engaged Pearl Meyer & Partners, LLC (“Pearl Meyer”), to conduct executive compensation consulting services starting in 2023. Pearl Meyer reports directly to the committee. While conducting assignments, Pearl Meyer interacts with the Compensation Committee, members of the Board of Directors, and senior management as needed. The Compensation Committee has the sole discretion to retain or obtain advice from, oversee, and terminate any compensation consultant, legal counsel, or other adviser to the Committee, and is directly responsible for the appointment, compensation, and oversight of any work of such adviser retained by the Committee. The


Company will provide appropriate funding (as determined by the Committee) for the payment of reasonable compensation to any such adviser.

The scope of the Pearl Meyer engagement includes assisting the Committee as requested in pre-planning meetings to discuss and finalize the Committee agendas and review materials to be presented to the full Committee; work with the Company or its outside counsel to review proxy disclosures pertaining to executive compensation; issue an annual letter to the Committee which will summarize its annual advisory services and independence as required under Nasdaq rules; assist counsel as necessary to develop the descriptive text to properly support the executive compensation disclosure tables; and work directly with the Compensation Committee to develop the Compensation Committee Report.

The Compensation Committee evaluated the independence of Pearl Meyer to assess whether their work raised conflicts of interest under Nasdaq listing standards and SEC rules. Based on this review, Pearl Meyer was determined to be independent and their work did not raise any conflicts of interest.

Nominating and Corporate Governance Committee

Mr. Ruiz and Mr. Quesada serve on the Nominating and Corporate Governance Committee. Mr. Ruiz serves as the Chairperson of the Nominating and Corporate Governance Committee. The Nominating and Corporate Governance Committee operates under a written charter adopted by the Board of Directors. The charter contains a detailed description of the scope of the Nominating and Corporate Governance Committee’s responsibilities and how they will be carried out. The Nominating and Corporate Governance Committee’s charter is available on our website at https://investor.lifewallet.com, in the “Documents & Charters” section in the “Corporate Governance” tab. The information on our website shall not be deemed incorporated by reference in this proxy statement. The Nominating and Corporate Governance Committee did not hold any meetings during the year ended December 31, 2022.

The Nominating and Corporate Governance Committee’s duties, which are specified in our Nominating and Corporate Governance Committee’s charter, include, but are not limited to:

A.
Nominating and Governance Oversight
identify, screen, and recommend director candidates for election or re-election;
oversee Company policies and procedures with respect to director candidates;
review and recommend for modification, approval, and disclosure of policies and procedures for identifying and screening board nominees, criteria used for evaluation of board member nominees, and policies regarding diversity of the board;
annually review relationships between the directors and the Company for independence;
assess the appropriateness of directors continuing to serve on the Board;
assess periodically the size and composition of the Board and recommend changes;


review the Board’s leadership structure and recommend changes;
review the Board committee structures and recommend committee appointments;
develop, oversee, and coordinate with management on director orientation programs;
recommend to the Board the methodology for and coordinate and oversee the periodic self-evaluation of the Board and its committees;
develop and recommend to the Board, and periodically review and recommend modifications to, the Corporate Governance Guidelines and other governance policies of the Company; and
review and report on or make recommendations to the Board about significant emerging corporate governance issues and practices.
B.
Self-Evaluation, Reporting, and Other
conduct period self-evaluations of the Nominating and Corporate Governance Committee performance;
report regularly to the Board of Directors; and
undertake such other responsibilities delegated to the Nominating and Corporate Governance Committee from time to time.

Process and Considerations for Nominating Board Candidates

The Board’s objective is that its membership be composed of a diverse group of experienced and dedicated individuals. The Nominating and Corporate Governance Committee is responsible for identifying, evaluating, recruiting, and recommending qualified candidates to the Board for nomination or election and for filling vacancies occurring between annual meetings of stockholders. Candidates for membership on the Board will be reviewed in the context of the existing membership of the Board, the operating requirements of the Company, and the long-term interests of stockholders. A director’s qualifications in light of these criteria are considered at least each time such director is renominated for Board membership. The Nominating and Corporate Governance Committee may apply several criteria in selecting nominees. At a minimum, the Nominating and Corporate Governance Committee considers:

Personal qualities and characteristics, accomplishments and reputation in the business community;
Current knowledge and contacts in the communities in which the Company does business and in the Company’s industry or other industries relevant to the Company’s business;
Ability and willingness to commit adequate time to Board and committee matters;


The fit of the individual’s skills and personality with those of other directors and potential directors in building a Board that is effective, collegial, and responsive to the needs of the Company; and
Diversity of viewpoints, background, experience and other demographics.

Board Operations

The Board directs and oversees the management of the business and affairs of the Company in a manner consistent with the best interests of the Company. The Board’s responsibility is one of oversight, and in performing its oversight role, the Board serves as the ultimate decision-making body of the Company, except for those matters reserved to or shared with our stockholders.

The Board selects its chairperson and the Company’s Chief Executive Officer in the manner and based on the criteria that the Board deems appropriate. Therefore, the Board does not have abouta policy on whether the Extensionroles of Chairperson and Chief Executive Officer should be separate or combined and, if it is to be separate, whether the Chairperson should be selected from the independent directors. At the present time, Mr. Ruiz serves as the Chairperson of the Board. The Board believes that the current leadership structure is in the best interest of the Company and its stockholders given Mr. Ruiz’s role in co-founding and leading the Company. Mr. Ruiz possesses detailed and in-depth knowledge of the issues, opportunities, and challenges facing the Company in its business and is thus best positioned to develop agendas that ensure that the Board’s time and attention are focused on the most critical matters relating to the business of the Company. His combined role enables decisive leadership, ensures clear accountability, and enhances the Company’s ability to communicate its message and strategy clearly and consistently to the Company’s stockholders, employees, and clients.

In addition, the Board believes that the leadership structure enables the Board to focus on key policy and operational issues and helps the Company operate in the best interests of its stockholders. The Board has not designated a lead director. The independent directors call, plan, and chair their executive sessions collaboratively and, between board meetings, communicate with management and one another directly. Under these circumstances, the directors believe designating a lead director to take on responsibility for functions in which they all currently participate might detract from rather than enhance performance of their responsibilities as directors. The Company believes that these arrangements afford the independent directors sufficient resources to supervise management effectively, without being overly engaged in day-to-day operations.

Board Oversight of Enterprise Risk

The Board is actively involved in the oversight and management of risks that could affect the Company. This oversight and management is conducted primarily through the committees of the Board identified above, but the full Board has retained responsibility for general oversight of risks. The Audit Committee is primarily responsible for overseeing the risk management function, specifically with respect to management’s assessment of risk exposures (including risks related to cyber, liquidity, credit, operations, and regulatory compliance, among others), and the processes in place to monitor and control such exposures. The other committees of the Board consider the risks within their areas of responsibility. The Board satisfies its oversight responsibility through full reports by contactingeach committee chair regarding the committee’s considerations and actions, as well as through regular reports directly from officers responsible for oversight of particular risks within the Company.


Director Independence

Our Board has determined that five of our directors, Michael F. Arrigo, Beatriz Assapimonwait, Thomas Hawkins, Ophir Sternberg, and Roger Meltzer, qualify as “independent” directors within the meaning of the independent director guidelines of Nasdaq and applicable SEC rules. The Nasdaq independence definition includes a series of objective tests regarding a director’s independence and requires that the Board make an affirmative determination that a director has no relationship with us that would interfere with such director’s exercise of independent judgment in carrying out the responsibilities of a director. As part of the Board’s determination, among other factors, the Board considered certain relationships of directors, including employment by LifeWallet.

Anti-Hedging and Anti-Pledging Policies

The Company has policies prohibiting (1) each director, officer, consultant, and employee of the Company from trading in options, puts and calls or similar instruments on securities of the Company, including shares of Common Stock or preferred stock and warrants (“LifeWallet Securities”), or selling LifeWallet Securities “short,” including a “sale against the box;” (2) each director, officer, and employee of the Company, each such person’s spouse, minor children and anyone else living in such person’s household, partnerships in which such person is a general partner, trusts of which such person is a trustee, estates of which such person is an executor and other equivalent legal entities that such person controls from holding LifeWallet Securities in margin accounts; and (3) each director, officer, consultant and employee of the Company from pledging LifeWallet Securities when he or she has knowledge of material information concerning the Company that has not been disclosed to the public.

Communications with the Company and the Board

Stockholders may communicate with the Company through its Investor Relations Department by writing to: Investor Relations, MSP Recovery, Inc., 2701 South Le Jeune Road, Floor 10, Coral Gables, Florida 33134 or via email at investors@lifewallet.com.

Stockholders interested in communicating with our Board, any Board committee, any individual director, or any group of directors (such as our independent directors) should send written correspondence to MSP Recovery, Inc. Board of Directors, Attn: Corporate Secretary, 2701 South Le Jeune Road, Floor 10, Coral Gables, Florida 33134. The Corporate Secretary will forward all such communications directly to our Board, such Board committee, such individual director, or such group of directors, as applicable.

Householding of Meeting Materials

Unless we have received contrary instructions from one or more of the affected stockholders, we will send a single copy of our 2022 Annual Report and 2023 Proxy Statement or Notice of Internet Availability to any household at which two or more stockholders reside. Each stockholder in the household will continue to receive a separate proxy card. This process, known as “householding,” reduces the volume of duplicate information received at your household and helps to reduce our expenses.

If, at any time, a stockholder no longer wishes to participate in “householding,” and would prefer to receive a separate copy of the 2022 Annual Report and 2023 Proxy Statement or Notice of Internet Availability, and/or wishes to receive separate copies of annual reports and proxy statements or


Notices of Internet Availability in the future, or if, at any time, stockholders who share an address and receive separate copies of the 2022 Annual Report and 2023 proxy Statement or Notice of Internet Availability would like to receive a single copy of our annual report and proxy statement or Notice of Internet Availability in the future, such stockholder or stockholders may (1) notify its or their broker or brokers or (2) direct its or their written request to Investor Relations and General Counsel, MSP Recovery, Inc., 2701 South Le Jeune Road, Floor 10, Coral Gables, Florida 33134.

Upon written or oral request of a stockholder at a shared address to which a single copy of the 2022 Annual Report and 2023 Proxy Statement or Notice of Internet Availability was delivered, we will deliver promptly separate copies of these documents.

Delinquent Section 16(a) Reports

Section 16(a) of the Securities Exchange Act of 1934, as amended, requires the Company’s officers and directors, and greater than 10% shareholders, to file reports of ownership and changes in ownership of the Company’s securities with the Securities and Exchange Commission. Copies of the reports are required by SEC regulation to be furnished to the Company. We believe that, during 2022, our directors, executive officers, and 10% stockholders complied with all Section 16(a) filing requirements, except for: (i) a late Form 4 filing by Frank C. Quesada dated June 8, 2022 to report the purchase warrants by the reporting person; (ii) a late Form 4/A filing by Frank C. Quesada dated June 14, 2022 to report the purchase warrants by the reporting person; (iii) a late Form 4 filing by Michael F. Arrigo dated June 3, 2022 to report the purchase of Class A common shares by the reporting person; and (iv) a late Form 4 filing by John H. Ruiz dated November 23, 2022 to report to report the purchase of Class A common shares by the reporting person.


AUDIT COMMITTEE REPORT

Pursuant to rules adopted by the SEC designed to improve disclosures related to the functioning of corporate audit committees and to enhance the reliability and credibility of financial statements of public companies, the Audit Committee of our Board of Directors submits the following report:

Audit Committee Report to Stockholders

The Audit Committee of the Board of Directors is responsible for providing independent, objective oversight of the Company’s accounting functions and internal controls. The Audit Committee is composed of three directors, each of whom is independent as defined by the Listing Rules. The Audit Committee operates under a written charter approved by the Board of Directors and held eleven meetings in fiscal 2022. A copy of the charter is available on the Company’s website at https://investor.lifewallet.com, in the “Documents & Charters” section in the “Corporate Governance” tab.

Management is responsible for the Company’s internal controls over financial reporting, disclosure controls and procedures, and the financial reporting process. The independent registered public accounting firm is responsible for performing an independent audit of the Company’s consolidated financial statements and the effectiveness of the Company’s internal control over financial reporting in accordance with Public Company Accounting Oversight Board (PCAOB) standards and to issue reports thereon. The Audit Committee’s responsibility is to monitor and oversee these processes, including the activities of the Internal Audit function. The Audit Committee has established a mechanism to receive, retain, and process complaints on auditing, accounting and internal control issues, including the confidential, anonymous submission by employees, vendors, customers and others of concerns on questionable accounting and auditing matters.

In connection with these responsibilities, the Audit Committee met with management and the independent registered public accounting firm to review and discuss the December 31, 2022 audited consolidated financial statements. The Audit Committee also discussed with the independent registered public accounting firm the matters required by Statement on Auditing Standards Update No. 61, as amended (AICPA, Professional Standards, Vol. 1, AU section 380), as adopted by the PCAOB in Rule 3200T. In addition, the Audit Committee received the written disclosures from the independent registered public accounting firm required by applicable requirements of the PCAOB regarding the independent accountant’s communications with the Audit Committee concerning independence, and the Audit Committee has discussed the independent registered public accounting firm’s independence from the Company and its management.

Based upon the Audit Committee’s discussions with management and the independent registered public accounting firm, and the Audit Committee’s review of the representations of management and the independent registered public accounting firm, the Audit Committee recommended that the Board of Directors include the audited consolidated financial statements in the Company’s Annual Report on Form 10-K for fiscal 2022 filed with the SEC.


The Audit Committee also has appointed, subject to stockholder ratification, Deloitte as the Company’s independent registered public accounting firm for fiscal 2023.

Respectfully submitted,

THE AUDIT COMMITTEE

Thomas Hawkins, Chair

Michael F. Arrigo

Roger Meltzer

This Audit Committee report shall not be deemed to be “soliciting material” or to be “filed” with the SEC or subject to Regulation 14A promulgated by the SEC or to the liabilities of Section 18 of the Exchange Act, and shall not be deemed incorporated by reference into any prior or subsequent filing by Palantir under the Securities Act or the Exchange Act, except to the extent Palantir specifically requests that the information be treated as “soliciting material” or specifically incorporates it by reference.


EXECUTIVE COMPENSATION

The following table presents information regarding the total compensation awarded to, earned by, and paid to the named executive officers of LifeWallet for services rendered to LifeWallet in all capacities for the years indicated.

Summary Compensation Table 5

Name and Principal Position

Year

Salary
($)
1

Bonus
($)

All Other
Compensation
($)
2

Total
($)

John H. Ruiz 3

2022

$964,507

$427,382

$1,391,889

     Chief Executive Officer

2021

$739,832

$739,832

Frank C. Quesada 4

2022

$318,339

$190,365

$508,704

     Chief Legal Officer

2021

$355,750

$355,750

Ricardo Rivera

2022

$506,130

$506,130

     Chief Operating Officer & interim CFO

2021

$400,000

$75,000

$475,000

1.
The salary amounts represent the actual amounts paid during the fiscal year.
2.
Amounts reported in the “All Other Compensation” column reflect amounts paid to our named executive officers by the Law Firm for their services to the Company. The relationship between the Company and the Law Firm, which is an entity that is not part of the Business Combination, is fully described in “Certain Relationships and Related Party Transactions—Certain Relationships and Related Party Transactions-The Company—Legal Services-MSP Recovery Law Firm.” Except as detailed below, in 2022 and 2021, the total amount of perquisites and personal benefits for each of the NEOs was less than $10,000.
3.
All Other Compensation includes: In 2022: $89,832 paid by the Law Firm for life insurance premium and $48,000 for personal security paid by Law Firm to a limited liability company.
4.
All Other Compensation includes: In 2021: $350,000 paid by the Law Firm to a limited liability company, which is owned by Mr. Quesada.
5.
During the years 2022 and 2021, the NEOs did not receive Stock Awards, Option Awards, Nonequity incentive plan compensation nor Nonqualified deferred compensation earnings.

Narrative Disclosure to Summary Compensation Table

For 2022, the principal elements of compensation provided to the named executive officers were base salaries, bonuses, and broad-based employee benefits.

Base Salary

During 2022, each of our named executive officers received an annual base salary from the Company as a fixed component of compensation. See the “Summary Compensation Table.” Base salaries were either determined when the named executive officers entered into their employment agreements or were determined by the Compensation Committee, and are intended to attract and retain individuals with superior talent commensurate with their relative expertise and experience. Considerations in determining base salary amounts include the executive’s performance, level of responsibility, experience, and comparative salaries in the marketplace.

Cash Bonus Compensation

The Company did not pay cash bonuses to any of the named executive officers during the fiscal year ended December 31, 2022.


Equity Compensation

The Company did not issue any equity compensation in the fiscal year ended December 31, 2022. The Company intends to issue equity awards under the Incentive Plan, a copy of which is filed as an Exhibit 10.16 to our Form S-1 Registration Statement filed on November 30, 2022.

Outstanding Equity Awards at Fiscal Year-End

As of December 31, 2022, the named executive officers did not have any outstanding equity awards.

Fiscal Year 2022 Non-Employee Director Compensation Table

The Board determines the form and amount of director compensation after its review of recommendations made by the Compensation Committee. The following table provides information regarding the total compensation that was earned by or paid to each of our non-employee directors during the fiscal year ended December 31, 2022. Other than as set forth in the table and described below, we did not pay any compensation, make any equity awards or non-equity awards to, or pay any other compensation to any of the non-employee members of our Board of Directors. John H. Ruiz, our Chief Executive Officer, did not receive any compensation for his service as a member of our Board of Directors during 2022. Frank C. Quesada, our Chief Legal Officer, did not receive any compensation for his service as a member of our Board of Directors during 2022. To the extent applicable, we reimburse non-employee directors for travel expenses incurred in attending meetings of our Board of Directors or any committee thereof.

2022 Non-Employee Director Compensation Table

Name

Fees Earned or
Paid in Cash ($)

Stock Awards ($) (1)

Option Awards ($)

Non-Equity Incentive Plan Compensation ($)

All Other Compensation ($)

Total Compensation (1)

Ophir Sternberg

$43,168

$100,725

$143,893

Beatriz Assapimonwait

$54,704

$100,725

$155,429

Michael Arrigo

$73,525

$100,725

$174,250

Thomas Hawkins

$64,418

$100,725

$165,143

Roger Meltzer

$58,346

$100,725

$159,071

1.
Stock awards are earned and issuable to non-employee directors after one full year of service. As of September 22, 2023, these stock awards have been earned, but have not yet been paid.

Narrative Disclosure to Non-Employee Director Compensation Table

During the fiscal year ended December 31, 2022, the Compensation Committee and the Board determined that each non-employee director was entitled to receive a $143,893 retainer per year regardless of committee services, paid in 30% cash and 70% equity. In addition to the $143,893 retainer for each non-employee director, some directors received additional payment as follows:

$21,250 cash retainer per year for the chairman of the audit committee or $15,179 cash retainer per year for each other member of the audit committee; and
$15,179 cash retainer per year for the chairman of the compensation committee or $11,536 cash retainer per year for each other member of the compensation committee.

Compensation for our non-employee directors is not limited to the payments determined by our compensation policies. Our non-employee directors remain eligible to receive equity awards and cash


or other compensation as may be provided from time to time at the discretion of our Board. No such awards or payments were made in 2022.

Company Executive Officer and Director Compensation

The following address, telephone numberdisclosures concern employment agreements with the Company’s executive officers:

Employment Agreements.We have entered into Employment Agreements with John H. Ruiz and Frank C. Quesada.

Employment Agreement with John H. Ruiz

Mr. Ruiz serves as our Chief Executive Officer. Under the terms of his employment agreement, he will earn a base salary of not less than $1,800,000, subject to annual review for potential increase (but not decrease) by the Board. In addition, Mr. Ruiz is eligible to receive an annual cash performance bonus of up to 100% of his base salary, based upon the achievement of individual and Company performance objectives and subject to Board approval. In addition, Mr. Ruiz is entitled to: (i) participate in and be granted awards under the MSP Recovery Omnibus Incentive Plan effective as of May 18, 2022 at the discretion of the Board, (ii) participate in the employee benefit plans, including pension, medical, disability and life insurance offered by the Company, and (iii) reimbursement for all reasonable and necessary out-of-pocket business, entertainment and travel expenses.

During the term of Mr. Ruiz’s employment agreement, he will be bound by non-competition and non-solicitation obligations. Upon a termination of Mr. Ruiz’s employment without Cause (as defined in his employment agreement) or facsimile number:the resignation by Mr. Ruiz for Good Reason (as defined in his employment agreement), Mr. Ruiz will be entitled to receive all accrued, determined and unpaid compensation, a pro-rata bonus payment for the fiscal year of termination based on actual performance results for the full annual performance period and a severance payment of Mr. Ruiz’ base salary for a period of six months after the date of termination.

Employment Agreement with Frank C. Quesada

Mr. Quesada serves as our Chief Legal Officer. Under the terms of his employment agreement, he will earn a base salary of not less than $600,000, subject to annual review for potential increase (but not decrease) by the Board. In addition, Mr. Quesada is eligible to receive an annual cash performance bonus of up to 100% of his base salary, based upon the achievement of individual and Company performance objectives and subject to Board approval. In addition, Mr. Quesada is entitled to: (i) participate in and be granted awards under the MSP Recovery Omnibus Incentive Plan effective as of May 18, 2022 at the discretion of the Board, (ii) participate in the employee benefit plans, including pension, medical, disability and life insurance offered by the Company, and (iii) reimbursement for all reasonable and necessary out-of-pocket business, entertainment and travel expenses.

During the term of Mr. Quesada’s employment agreement, he will be bound by non-competition and non-solicitation obligations. Upon a termination of Mr. Quesada’s employment without Cause (as defined in his employment agreement) or the resignation by Mr. Quesada for Good Reason (as defined in his employment agreement), Mr. Quesada will be entitled to receive all accrued, determined and unpaid compensation, a pro-rata bonus payment for the fiscal year of termination based on actual


performance results for the full annual performance period and a severance payment of Mr. Quesada’s base salary for a period of six months after the date of termination.


CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

Related Person Policy

Our Corporate Governance Guidelines requires us to avoid or adequately disclose related party transactions that could result in actual or potential conflicts of interests, except under guidelines approved by the Board of Directors (or the Audit Committee). Pursuant to our Related Person Transaction Policy, related-person transactions are defined as transactions or arrangements or a series of transactions or arrangements in which: (i) the Company (including, for the avoidance of doubt, its direct and indirect subsidiaries and controlled entities) participates (whether or not the Company is a party), and (ii) a Related Person has a direct or indirect material interest in such transaction. A conflict-of-interest situation can arise when a person takes actions or has interests that may make it difficult to perform his or her work objectively and effectively or interferes (or appears to interfere) with the Company’s interests. Our Related Person Transaction Policy applies to: (i) Board members; (ii) Executive Officers; (iii) nominees for election to the Board; (iv) stockholders known to the Company to own of record or beneficially more than 5% of any class of the Company’s voting securities; and (v) Immediate Family Members (as defined therein) of any of the foregoing persons.

Our Audit Committee, pursuant to its written charter, is responsible for reviewing and approving related-party transactions to the extent we enter into such transactions. The Committee shall review all Related Person Transactions reported to the Committee and may, in its discretion based upon a determination that such transactions are in the best interests of the Company and such other determinations as the Committee deems appropriate: (i) approve or ratify such transactions, as applicable, (ii) request that the transaction be modified as a condition to the Committee’s approval or ratification, or (iii) reject the transaction. Such transactions will require prior approval by our Audit Committee and, to the extent required by Section 144 of the Delaware General Corporation Law (the “DGCL”), a majority of our disinterested directors or members of the committee to which such transaction is presented for approval. We will not enter into any such transaction unless our Audit Committee and, to the extent required by the DGCL, a majority of our disinterested directors or members of the committee to which such transaction is presented for approval determine that the terms of such transaction are no less favorable to us than those that would be available to us with respect to such a transaction from unaffiliated third parties.

These procedures are intended to determine whether any such related party transaction impairs the independence of a director or presents a conflict of interest on the part of a director, employee or officer.

Advances and Promissory Notes

Pursuant to a loan agreement dated May 20, 2022, John H. Ruiz and Frank C. Quesada provided a cash loan to the Company in the amount of $13,272,176.64 in order to satisfy the Service Fee Account condition as described in the Membership Interest Purchase Agreement dated July 11, 2021 (the “Closing Loan”). The Closing Loan has an annual interest rate of 4% and was set to mature on November 23, 2022; however, the maturity date of the Closing Loan may be extended, at the option of the Company, for up to three successive six-month periods (for a total of 24 months). The Company exercised this right and extended the maturity date of the Closing Loan. This loan agreement was ratified by the Audit Committee on June 15, 2022.


Pursuant to a loan agreement dated June 16, 2022, La Ley con John H. Ruiz d/b/a MSP Recovery Law Firm and MSP Law Firm, PLLC (collectively, “Law Firm”) made a cash loan to the Company in the amount of approximately $112,000,000 (the “New Loan”) in order to: (i) to fund the obligations to pay costs and expenses incurred in connection with the SPAC transaction undertaken by Lionheart II Holdings, LLC, and (ii) to fund operating expenses and other obligations of MSP Recovery, Inc., including repayment of certain funds that had been previously advanced to the Company by John H. Ruiz and Frank C. Quesada of approximately $24,000,000. The NewLoan has an annual interest rate of 4%, paid in kind, and will mature four years from the effective date of the New Loan, with no prepayment penalty. This loan agreement was approved by the Audit Committee on June 15, 2022.

In addition to the New Loan, on February 22, 2023, La Ley con John H. Ruiz, P.A. d/b/a MSP Recovery Law Firm advanced $4.95 million to the Company to cover certain expenses (the “Bridge Loan”). The Bridge Loan does not accrue interest on the unpaid balance and becomes due and payable two years from the date of the final advance from the Working Capital Credit Facility (as defined and discussed in Note 10: Claims Financing Obligations and Notes Payable of our Quarterly Report on Form 10-Q for the period ending March 31, 2023). Pursuant to its terms, the Company can prepay the Bridge Loan at any time, without penalties, fees, or other expenses.

Legal Services Agreement

At the closing of the business combination between the Company and Lionheart Acquisition Corporation II,
4218 NE 2nd Avenue
Miami, Florida 33137
Tel: (305) 573-3900

In order the Company entered into a Legal Services Agreement (“LSA”) with La Ley con John H. Ruiz, P.A. d/b/a MSP Recovery Law Firm and MSP Law Firm, PLLC (collectively the “Law Firm”), dated May 23, 2022. Pursuant to receive timely deliverythe LSA, the Company engaged the Law Firm to act as its exclusive lead counsel to represent the Company, and each of its subsidiaries, as it pertains to certain assigned claims, causes of actions, proceeds, products, and distribution. Under the LSA, the Company will pay the Law Firm all of the documents in advanceLaw Firm’s documented costs related to representation of the special meeting, you must make your request for information no later than January 20, 2022.

28


ANNEX A
PROPOSED AMENDMENT
TO THE
AMENDED AND RESTATED
CERTIFICATE OF INCORPORATION
OF
LIONHEART ACQUISITION CORPORATION II
Pursuant to Section 242 of the
Delaware General Corporation Law
The undersigned, being a duly authorized officer of LIONHEART ACQUISITION CORPORATION II (the “Corporation”), a corporation existing under the laws of the State of Delaware, does hereby certify as follows:
1.   The name of the Corporation is Lionheart Acquisition Corporation II.
2.   The Corporation’s Certificate of Incorporation was filed in the office of the Secretary of State of the State of Delaware on December 23, 2019. An Amended and Restated Certificate of Incorporation was filed in the office of the Secretary of State of the State of Delaware on August 13, 2020.
3.   This Amendment to the Amended and Restated Certificate of Incorporation further amends the Amended and Restated Certificate of Incorporation of the Corporation.
4.   This Amendment to the Amended and Restated Certificate of Incorporation was duly adopted by the affirmative vote of the holders of at least 65% of the stock entitled to vote at a meeting of stockholdersCompany or its subsidiaries approved in accordance with ARTICLE NINTHan agreed budget. For the services described in the LSA, the Law Firm will be entitled to: (i) any attorneys’ fees that are awarded to the Law Firm pursuant to a fee shifting statute by agreement or court award in such case, and (ii) an amount, if greater than zero, equal to the difference between 40% of the recovery proceeds due to the Company or its subsidiaries for recovered claims, less any amount due to the Law Firm under the foregoing clauses ((i) and (ii) together, the “Compensation”).

The LSA also contains an advance provision, whereby the Company will advance to the Law Firm a monthly amount equal to: (x) $1,000,000 of the Compensation due to the Law Firm to fund certain resources necessary to provide services by the Law Firm, plus (y) overhead costs (i.e., salaries rent, utilities, and similar expenses; provided that any compensation paid to John H. Ruiz or Frank Quesada by the Law Firm shall not be included in such overhead costs) to operate the Law Firm in an amount necessary to pay such overhead costs reasonably anticipated by the Law Firm to become due in such month. This Advance shall be offset from the Compensation, and in the event that the Legal Services Agreement is terminated, certain additional fees may become payable to the Law Firm pursuant to the terms of the Legal Services Agreement. The LSA was ratified by the Audit Committee on June 15, 2022.

Air Transportation Services Agreement

Historically, MSP has been provided with aviation services pursuant to an Air Transportation Services Agreement, dated June 3, 2019, by and between MSP Recovery Aviation, LLC (“MSP Aviation”) and


Series MRCS, a designated series of MDA Series, LLC, pursuant to which MSP Aviation agreed to provide Series MRCS and its affiliates with air transportation services via its private, non-commercial plane. In exchange for such services, Series MRCS agreed to reimburse MSP Aviation for aircraft rental and flight time along with related fees, expenses, and taxes in accordance with a lease agreement for each flight. MSP Aviation is owned by John H. Ruiz.

As of September 30, 2022 and December 31, 2021, $153 thousand and $153 thousand, respectively was due from MSP Aviation and included in the condensed consolidated balance sheets in Affiliate Receivable. For the three and nine months ended September 30, 2022, $150 thousand and $400 thousand, respectively was included in General and Administrative expenses related to MSP Aviation in the condensed consolidated statements of operations. For the three and nine months ended September 30, 2021, the amounts were de minimus. Management of MSP intends to continue its relationship with MSP Aviation under an informal arrangement that provides MSP and its representatives with economic terms that are at least no less favorable than the terms it would receive if it were to engage an unrelated third party to provide substantially similar services. This agreement was approved by the Audit Committee on June 15, 2022.

Registration Rights

The Company has entered into the Registration Rights Agreement August 13, 2020 with the Holders (as defined therein). Pursuant to the terms of the Amended and Restated Certificate of IncorporationRegistration Rights Agreement, (i) the Founder Shares and the provisionsshares of Sections 242Class A common stock issued or issuable upon the General Corporation Lawconversion of any Founder Shares, (ii) the Units (as defined therein), (iii) the shares of Class A common stock included in such Units, (iv) the Original Warrants included in such Units (including any shares of Class A common stock issued or issuable upon the exercise of any such Original Warrants), (v) the New Warrants (including any shares of Class A common stock issued or issuable upon the exercise of any such New Warrants), (vi) the equity securities that Nomura purchased from the Company pursuant to that certain Forward Purchase Agreement described in the section entitled “Business – Company History.” (the “Forward Purchase Shares”), (vii) any outstanding share of the StateClass A common stock or any other equity security (including the shares of Delaware (the “GCL”).

5.   The references to “18 months” in Article NINTH, sections 9.1(b), 9.2(d) and 9.7Class A common stock issued or issuable upon the exercise or conversion of any other equity security) of the Amended and Restated Certificate of Incorporation are hereby replaced and substituted for 24 months.
IN WITNESS WHEREOF, I have signed this Amendment to the Amended and Restated Certificate of Incorporation this     day of January, 2022.
Name:
Title:



PROXY
Lionheart Acquisition Corporation II
4218 NE 2nd Avenue
Miami, Florida 33137
SPECIAL MEETING OF STOCKHOLDERS
JANUARY 27, 2022
YOUR VOTE IS IMPORTANT
FOLD AND DETACH HERE
LIONHEART ACQUISITION CORPORATION II
THIS PROXY IS SOLICITED BY THE BOARD OF DIRECTORS
FOR THE SPECIAL MEETING OF STOCKHOLDERS TO BE HELD ON
JANUARY 27, 2022
The undersigned, revoking any previous proxies relating to these shares, hereby acknowledges receiptCompany held by a Holder as of the Notice and Proxy Statement, dated January 4, 2022,date of the Registration Rights Agreement, (viii) any shares of the Company issued or to be issued to any Additional Holders (as defined in the Registration Rights Agreement) in connection with the special meeting of stockholders (the “Special Meeting”) to be held at 11:00 a.m. Eastern Time on January 27, 2022 as a virtual meeting for the sole purpose of consideringBusiness Combination and voting upon the following proposals, and hereby appoints Ophir Sternberg and Paul Rapisarda, and each of them (with full power to act alone), the attorneys and proxies(ix) any other equity security of the undersigned,Company issued or issuable with power of substitutionrespect to each, to vote all sharesany of the common stock, of Lionheart Acquisition Corporation II (the “Company”) registeredsecurities described in the name provided, which the undersigned isforegoing clauses (i) - (ix) by way of a stock dividend or stock split or in connection with a combination of shares, recapitalization, merger, consolidation or reorganization will be entitled to vote atcertain registration rights, subject to the Special Meetingterms and at any adjournments thereof, with all the powers the undersigned would have if personally present. Without limiting the general authorization hereby given, said proxies are, and each of them is, instructed to vote or act as follows on the proposalsconditions set forth in the Registration Rights Agreement.

The foregoing summary of the Registration Rights Agreement is not complete and is qualified in its entirety by reference to the complete text of the Registration Rights Agreement as set forth in an exhibit to the registration statement.

Virage Amendment

As disclosed in our Annual Report on Form 10-Q for the period ending June 30, 2023, on April 12, 2023, we entered into an amendment (the “Virage MTA Amendment”) to the Virage MTA and Virage Guaranty pursuant to which the payment date was extended from May 23, 2023 until September 30, 2024, subject


to acceleration upon certain triggering events. The payment obligation will become current at September 30, 2023, and the Company does not currently have available liquidity to satisfy such obligations. Under the Virage MTA Amendment, Virage received a first priority lien on all sources of revenue of the company not otherwise encumbered as of the date of the Virage MTA Amendment, to the extent in excess of the amount of revenues necessary to establish and maintain an operating reserve of $70 million for overhead expenses and applicable taxes. On July 24, 2023, the operating reserve was adjusted to $47.5 million and MSP Recovery agreed not to increase its 2023 operating budget without Virage’s consent.

On January 1, 2024, the Company will be required to make a one-time, lump sum payment to Virage for the period starting May 24, 2023 and ending December 31, 2023, in one or a combination of: (a) cash, in an amount equal to 1.0% of each calendar month-end balance (which month-end balance shall be increased daily up to 20% per annum based on a formula set forth in the Virage MTA Amendment) of the amount owing to Virage as of each preceding calendar month end and/or (b) warrants to purchase Class A common stock at $0.0001 per share, in an amount equal to the quotient of 1.0% of each calendar month-end balance (which month-end balance shall be increased daily up to 20% per annum based on a formula set forth in the Virage MTA Amendment) of the amount owing to Virage as of each preceding calendar month end and the volume weighted average price of a share of our Class A common stock for the five day period prior to the issuance. If paid in warrants, such warrants will expire on January 1, 2026.

Further, for each calendar month beginning with January 31, 2024 until the obligations to Virage are paid in full, the Company has agreed to pay to Virage an amount monthly, in one or a combination of: (a) cash, in an amount equal to 1.0% of each calendar month-end balance (which month-end balance shall be increased daily up to 20% per annum based on a formula set forth in the Virage MTA Amendment) of the amount owing to Virage as of each preceding calendar month end and/or (b) warrants to purchase Class A common stock at $0.0001 per share, in an amount equal to the quotient of 1.0% of each calendar month-end balance (which month-end balance shall be increased daily up to 20% per annum based on a formula set forth in the Virage MTA Amendment) of the amount owing to Virage as of each preceding calendar month end and the volume weighted average price of a share of our Class A common stock. If paid in warrants, such warrants will expire two years from the date of issuance.

The warrants will contain customary provisions for a transaction of this type, including that each warrant will be exercisable in whole or in part at any time prior to the expiration date, be freely transferable, subject only to applicable securities laws, and be subject to customary anti-dilution protection regarding the exercise price and number of shares of Class A Common Stock to be issued upon the exercise of each warrant.

In addition, the Virage MTA Amendment changed the payment methods to Virage to exclusively be, in the following order of priority: (a) the Proceeds and any other sources of revenue or liquidity of the Company (and its subsidiaries) that are not encumbered by a lien of a party other than Virage and to the extent such revenues and liquidity exceed the amount of net of revenues necessary to establish and maintain an operating reserve of $70 million (reduced to $47.5 million on July 24, 2023) for certain Company expenses, (b) a sale of certain reserved shares of Messrs. John H. Ruiz and Frank Quesada, and the delivery of the resulting net cash proceeds thereof to VRM, (c) Parent’s sale of additional shares and delivery of proceeds to Virage, subject to certain anti-dilution provisions, (d) if not satisfied by the foregoing, a sale by Messrs. Ruiz and Quesada other shares of Messrs. John H. Ruiz and Frank


Quesada, and the delivery of the resulting net cash proceeds thereof to VRM; provided that if the VRM Full Return is not fully paid by September 30, 2024 the VRM Full Return shall be payable by any of such payment methods in any order of priority. In addition, in connection therewith, Messrs. Quesada and Ruiz agreed to certain transfer restrictions applicable to their common stock, and agreed to effectuate sales of Company common stock in certain circumstances.

DELIVERY OF DOCUMENTS TO STOCKHOLDERS SHARING AN ADDRESS

To the extent we deliver a paper copy of the proxy materials to stockholders, the SEC rules allow us to deliver a single copy of proxy materials to any household at which two or more stockholders reside, if we believe the stockholders are members of the same family.

We will promptly deliver, upon oral or written request, a separate copy of the proxy materials to any stockholder residing at the same address as another stockholder and currently receiving only one copy of the proxy materials who wishes to receive his or her own copy. Requests should be directed to our Corporate Secretary by mail to MSP Recovery, Inc., 2701 South Le Jeune Road, Floor 10, Coral Gables, Florida 33134, by email at investors@lifewallet.com, or by phone at 305-614-2222.

OTHER MATTERS

Except as described in this Proxy Statement.Statement, the Board of Directors knows of no other matters to be presented at the Annual Meeting. If other matters that require the vote of the shareholders, including a question of adjourning the Annual Meeting, properly come before the Annual Meeting or any adjournment thereof, the holders of the proxies are authorized to vote on these matters in accordance with management’s discretion. The accompanying proxy card confers discretionary authority to take action with respect to any additional matters that may come before the Annual Meeting or any adjournment thereof.

Stockholders are referred to our Form 10-K for the year ended December 31, 2022 for financial and other information about the Company. In accordance with the rules of the SEC, we are furnishing our proxy materials, including this proxy statement and the Form 10-K, to our stockholders via the Internet at https://www.proxydocs.com/LIFW. In addition, such report and other reports we file with the SEC are available, free of charge, through the Investor Relations section of our website at https://investor.lifewallet.com. The information on our website shall not be deemed incorporated by reference in this proxy statement.

Copies of our Form 10-K for the year ended December 31, 2022, including the financial statements and the financial statement schedules (but excluding exhibits and information incorporated by reference), may be obtained without charge by first class mail or other equally prompt means within one (1) business day of receipt of such request by writing to Investor Relations, General Counsel and Corporate Secretary, MSP Recovery, Inc., 2701 South Le Jeune Road, Floor 10, Coral Gables, Florida 33134 or by sending an email to investors@lifewallet.com. The SEC maintains a web site that contains our reports, proxy statements, beneficial ownership information and other information that we file electronically with the SEC. The address of this site is http://www.sec.gov.


img191178444_8.jpg 

By Order of the Board of Directors,

img191178444_16.jpg 

John H. Ruiz

Chief Executive Officer

Chairman of the Board

LifeWallet

September 22, 2023

Please visit us at:

www.lifewallet.com

to learn discover how LifeWallet is disrupting the antiquated healthcare reimbursement system, using data analytics to identify and recover massive amounts of improper payments made by Medicare, Medicaid, and commercial insurers.

https://investor.lifewallet.com

for information about our stock price, earnings information, news releases, and SEC filings.


img191178444_17.jpg 

Please visit us at: www.lifewallet.com to learn discover how LifeWallet is disrupting the antiquated healthcare reimbursement system, using data analytics to identify and recover massive amounts of improper payments made by Medicare, Medicaid, and commercial insurers. https://investor.lifewallet.com for information about our stock price, earnings information, news releases, and SEC filings.


Appendix A


img191178444_18.jpg 

Barcode above Use the Internet to transmit your voting instructions and for electronic delivery of information up until 11:59 P.M. Eastern Time the day before the cut-off date or meeting date. Follow the instructions to obtain your records and to create an electronic voting instruction form. ELECTRONIC DELIVERY OF FUTURE PROXY MATERIALS If you would like to reduce the costs incurred by our company in mailing proxy materials, you can consent to receiving all future proxy statements, proxy cards and annual reports electronically via e-mail or the Internet. To sign up for electronic delivery, please follow the instructions above to vote using the Internet and, when prompted, indicate that you agree to receive or access proxy materials electronically in future years. VOTE BY PHONE - 1-866-460-4822 Use any touch-tone telephone to transmit your voting instructions up until 11:59 P.M. Eastern Time the day before the cut-off date or meeting date. Have your proxy card in hand when you call and then follow the instructions. VOTE BY MAIL Mark, sign and date your proxy card and return it in the postage-paid envelope we have provided or return it to Vote Processing, [Address], [City], [State] [Zip Code]. TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: MXXXXX-PXXXXX KEEP THIS PORTION FOR YOUR RECORDS DETACH AND RETURN THIS PORTION ONLY THIS PROXY CARD IS VALID ONLY WHEN EXECUTED, WILL BE VOTED IN THE MANNER DIRECTED HEREIN. IF NO DIRECTION IS MADE, THIS PROXY WILL BE VOTED “FOR” THE EXTENSION AMENDMENT PROPOSAL CONSISTING OF PROPOSAL 1 BELOW AND, “FOR” THE ADJOURNMENT PROPOSAL CONSISTING OF PROPOSALSIGNED. [COMPANY NAME] The Board of Directors recommends you vote FOR all 8 nominees listed and FOR proposals 2 and 3. 1. Election of Directors For Against Abstain Nominees: 1a. [Name] 1b. [Name] 1c. [Name] 1d. [Name] 1e. [Name] 1f. [Name] 1g. [Name] 1h. [Name] 2. Ratification of the appointment of [Auditor] as independent registered public accountants.

THE BOARD OF DIRECTORS RECOMMENDS A VOTE “FOR” PROPOSALS 1 AND 2.
3. Advisory approval of executive compensation. NOTE: In their discretion, the proxies are authorized to vote upon such other business as may properly come before the meeting or any adjournment thereof. For address changes and/or comments, please check this box and write them on the back where indicated. Please indicate if you plan to attend this meeting. Yes No Please sign exactly as your name(s) appear(s) hereon. When signing as attorney, executor, administrator, or other fiduciary, please give full title as such. Joint owners should each sign personally. All holders must sign. If a corporation or partnership, please sign in full corporate or partnership name by authorized officer. Signature [PLEASE SIGN WITHIN BOX] Date Signature (Joint Owners) Date


img191178444_19.jpg 

Important Notice Regarding the Availability of Proxy Materials for the special meetingAnnual Meeting: The Proxy Statement and the 2022 Annual Report on Form 10-K are available at www.proxyvote.com. [Company Name] Annual Meeting of Stockholders [Weekday], [Month] [Day], [Year] at [XX:XX a.m./p.m.], local time This proxy is solicited by the Board of Directors The undersigned hereby appoints [Name] and [Name], and each of them, with power to act without the other and with power of substitution, as proxies and attorneys-in-fact and hereby authorizes them to represent and vote, as provided on the other side, all the shares of [Company Name]. Common Stock which the undersigned is entitled to vote, and, in their discretion, to vote upon such other business as may properly come before the [Year] Annual Meeting of Stockholders of the company to be held on January 27, 2022: This notice of meeting and[Month] [Day], [Year], or at any adjournment or postponement thereof, with all powers which the accompany proxy statement are availableundersigned would possess if present at https://www.cstproxy.com/lionheartacquisitioncorpii/2022.

FORAGAINSTABSTAIN
Proposal 1 — Extension Amendment Proposal
Amend the Company’s amended and restated certificate of incorporation to extend the date that the Company has to consummate an initial business combination to August 18, 2022.
FORAGAINSTABSTAIN
Proposal 2 — Adjournment Proposal
Adjourn the Special Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of Proposal 1.



Dated: 2022
Stockholder’s Signature
Stockholder’s Signature
Signature should agree with name printed hereon. If stock is held in the name of more than one person, EACH joint owner should sign. Executors, administrators, trustees, guardians, and attorneys should indicate the capacity in which they sign. Attorneys should submit powers of attorney.
PLEASE SIGN, DATE AND RETURN THE PROXY IN THE ENVELOPE ENCLOSED TO CONTINENTAL STOCK TRANSFER & TRUST COMPANY.Annual Meeting. THIS PROXY WILL BE VOTED IN THE MANNERAS DIRECTED, HEREIN BY THE UNDERSIGNED STOCKHOLDER.OR IF NO DIRECTION IS MADE, THIS PROXYINDICATED, WILL BE VOTED “FOR” THE ELECTION OF ALL DIRECTORS AND “FOR” PROPOSALS SET FORTH IN PROPOSALS 1 AND 2 AND WILL GRANT DISCRETIONARY AUTHORITY TO VOTE UPON SUCH OTHER MATTERS AS MAY PROPERLY COME BEFORE THE SPECIAL MEETING OR ANY ADJOURNMENTS THEREOF. THIS PROXY WILL REVOKE ALL PRIOR PROXIES SIGNED BY YOU.

3. In their discretion, the proxies are authorized to vote upon such other business as may properly come before the Annual Meeting or any adjournment thereof. Address Changes/Comments: (If you noted any Address Changes/Comments above, please mark corresponding box on the reverse side.) Continued and to be signed on reverse side